US20190292188A1 - Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors - Google Patents
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors Download PDFInfo
- Publication number
- US20190292188A1 US20190292188A1 US16/285,787 US201916285787A US2019292188A1 US 20190292188 A1 US20190292188 A1 US 20190292188A1 US 201916285787 A US201916285787 A US 201916285787A US 2019292188 A1 US2019292188 A1 US 2019292188A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- membered heterocycloalkyl
- membered heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=CN2C(=N1)C(C)=C(C)N=C2N([1*])[H] Chemical compound *C1=CN2C(=N1)C(C)=C(C)N=C2N([1*])[H] 0.000 description 15
- HBVMWHDCCSNRSP-UHFFFAOYSA-N CC1=C(CNC2=NN3C(N)=NC(C4=CC=CC(C#N)=C4)=C(C4=NC=NC=C4)C3=N2)N=CC=C1 Chemical compound CC1=C(CNC2=NN3C(N)=NC(C4=CC=CC(C#N)=C4)=C(C4=NC=NC=C4)C3=N2)N=CC=C1 HBVMWHDCCSNRSP-UHFFFAOYSA-N 0.000 description 2
- MWOOCFNLLDAOEV-UHFFFAOYSA-N CC1=C(COC2=NN3C(N)=NC(C4=CC=CC(C#N)=C4)=C(C4=NC=NC=C4)C3=N2)N=CC=C1 Chemical compound CC1=C(COC2=NN3C(N)=NC(C4=CC=CC(C#N)=C4)=C(C4=NC=NC=C4)C3=N2)N=CC=C1 MWOOCFNLLDAOEV-UHFFFAOYSA-N 0.000 description 2
- OMQXXRAZWAPCLU-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C(Br)=CN=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C(Br)=CN=C23)=C1 OMQXXRAZWAPCLU-UHFFFAOYSA-N 0.000 description 2
- LWSUJFGIDCXOAS-UHFFFAOYSA-N CCNC(=O)C1=C(C#N)N2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 Chemical compound CCNC(=O)C1=C(C#N)N2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 LWSUJFGIDCXOAS-UHFFFAOYSA-N 0.000 description 2
- AVIFKRSKGYFYPM-UHFFFAOYSA-N CCNC(=O)C1=CN2C(NCC3=C(OC)C=C(OC)C=C3)=NC(C3=CC=CC=C3)=C(Br)C2=N1 Chemical compound CCNC(=O)C1=CN2C(NCC3=C(OC)C=C(OC)C=C3)=NC(C3=CC=CC=C3)=C(Br)C2=N1 AVIFKRSKGYFYPM-UHFFFAOYSA-N 0.000 description 2
- SASURQFBMHKHNM-UHFFFAOYSA-N CCNC(=O)C1=CN2C(NCC3=C(OC)C=C(OC)C=C3)=NC(C3=CC=CC=C3)=C(C3=CCN(C(=O)OC(C)(C)C)CC3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(NCC3=C(OC)C=C(OC)C=C3)=NC(C3=CC=CC=C3)=C(C3=CCN(C(=O)OC(C)(C)C)CC3)C2=N1 SASURQFBMHKHNM-UHFFFAOYSA-N 0.000 description 2
- QGLVSJMLEQJHQS-UHFFFAOYSA-N CCOC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=CC2=N1 Chemical compound CCOC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=CC2=N1 QGLVSJMLEQJHQS-UHFFFAOYSA-N 0.000 description 2
- RIVMGBVKGDWHKU-UHFFFAOYSA-N CCOC(=O)C1=CN2C(NCC3=CC=C(OC)C=C3OC)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 Chemical compound CCOC(=O)C1=CN2C(NCC3=CC=C(OC)C=C3OC)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 RIVMGBVKGDWHKU-UHFFFAOYSA-N 0.000 description 2
- ARLLGMIDIQJMMN-UHFFFAOYSA-N COC1=CC(C2=C(C3=CC=NC=C3)C3=NC=CN3C(N)=N2)=CC=C1 Chemical compound COC1=CC(C2=C(C3=CC=NC=C3)C3=NC=CN3C(N)=N2)=CC=C1 ARLLGMIDIQJMMN-UHFFFAOYSA-N 0.000 description 2
- JYKKEFUGIQDCEP-UHFFFAOYSA-N COC1=NC(C2=CC=CC=C2)=C(Br)C(N)=N1 Chemical compound COC1=NC(C2=CC=CC=C2)=C(Br)C(N)=N1 JYKKEFUGIQDCEP-UHFFFAOYSA-N 0.000 description 2
- HGBNOIRPMHJQAR-UHFFFAOYSA-N CS(=O)(=O)OCC1=NN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC=NC=N3)C2=N1 Chemical compound CS(=O)(=O)OCC1=NN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC=NC=N3)C2=N1 HGBNOIRPMHJQAR-UHFFFAOYSA-N 0.000 description 2
- SEDFONKMAJCCMZ-UHFFFAOYSA-N ClC1=NC(Cl)=C(Br)C2=NC=CN12 Chemical compound ClC1=NC(Cl)=C(Br)C2=NC=CN12 SEDFONKMAJCCMZ-UHFFFAOYSA-N 0.000 description 2
- ZTOHVLOXNPNZJK-UHFFFAOYSA-N N#CC1=CC(C2=C(C3=CC=NC=N3)C3=NC(COC4=C(C#N)C=CC=C4)=NN3C(N)=N2)=CC=C1 Chemical compound N#CC1=CC(C2=C(C3=CC=NC=N3)C3=NC(COC4=C(C#N)C=CC=C4)=NN3C(N)=N2)=CC=C1 ZTOHVLOXNPNZJK-UHFFFAOYSA-N 0.000 description 2
- USUJGMZEOPRMRJ-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(O)C4=C(F)C=CC=C4F)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(O)C4=C(F)C=CC=C4F)=NN3C(N)=N2)=C1 USUJGMZEOPRMRJ-UHFFFAOYSA-N 0.000 description 2
- RDPSXBYQPVBBIA-UHFFFAOYSA-N CC(C)C(=O)N1CC(O)C1.CC(C)C(=O)NC1=CN(CCO)N=C1 Chemical compound CC(C)C(=O)N1CC(O)C1.CC(C)C(=O)NC1=CN(CCO)N=C1 RDPSXBYQPVBBIA-UHFFFAOYSA-N 0.000 description 1
- HYBMBAGWDRYZRE-UHFFFAOYSA-M CC.CC.CC(=O)C1=CN2C(N)=NC(C)=C(C)C2=N1.CC(=O)C1=CN2C(N)=NC(C)=C(C)C2=N1.CC1=CC2=NC(C)=CN2C(N)=N1.CC1=CN2C(N)=NC(C)=C(C)C2=N1.CC1=CN2C(N)=NC(Cl)=CC2=N1.CCC(=O)[Ra]OC=O.NC1=NC(N)=NC(Cl)=C1 Chemical compound CC.CC.CC(=O)C1=CN2C(N)=NC(C)=C(C)C2=N1.CC(=O)C1=CN2C(N)=NC(C)=C(C)C2=N1.CC1=CC2=NC(C)=CN2C(N)=N1.CC1=CN2C(N)=NC(C)=C(C)C2=N1.CC1=CN2C(N)=NC(Cl)=CC2=N1.CCC(=O)[Ra]OC=O.NC1=NC(N)=NC(Cl)=C1 HYBMBAGWDRYZRE-UHFFFAOYSA-M 0.000 description 1
- UWQYMGROHBJEED-UHFFFAOYSA-N CC1=C(B2OC(C)(C)C(C)(C)O2)OC=N1 Chemical compound CC1=C(B2OC(C)(C)C(C)(C)O2)OC=N1 UWQYMGROHBJEED-UHFFFAOYSA-N 0.000 description 1
- NIHXCBADWGREIZ-UHFFFAOYSA-N CC1=C(C)C2=NC(CCCO)=NN2C(N)=N1.CC1=C(C)C2=NC(CO)=NN2C(N)=N1.CCC1=NN2C(N)=NC(C)=C(C)C2=N1.CCCCC1=NN2C(N)=NC(C)=C(C)C2=N1.CCCCC1=NN2C(N)=NC(C)=C(C)C2=N1.CCCO Chemical compound CC1=C(C)C2=NC(CCCO)=NN2C(N)=N1.CC1=C(C)C2=NC(CO)=NN2C(N)=N1.CCC1=NN2C(N)=NC(C)=C(C)C2=N1.CCCCC1=NN2C(N)=NC(C)=C(C)C2=N1.CCCCC1=NN2C(N)=NC(C)=C(C)C2=N1.CCCO NIHXCBADWGREIZ-UHFFFAOYSA-N 0.000 description 1
- AUGDEEGDAZMGRW-UHFFFAOYSA-N CC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)C=CN=C1 Chemical compound CC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)C=CN=C1 AUGDEEGDAZMGRW-UHFFFAOYSA-N 0.000 description 1
- KQXHUEIHFWZGFB-UHFFFAOYSA-N CC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)OC=N1 Chemical compound CC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)OC=N1 KQXHUEIHFWZGFB-UHFFFAOYSA-N 0.000 description 1
- BORCFMVZXWVBNM-UHFFFAOYSA-N CC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=NN(C)C=C4)N=C23)OC=N1 Chemical compound CC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=NN(C)C=C4)N=C23)OC=N1 BORCFMVZXWVBNM-UHFFFAOYSA-N 0.000 description 1
- WLEVMDSFOICAKH-UHFFFAOYSA-N CC1=C(C2=C(C3=CC=NC=C3)C3=NC=CN3C(N)=N2)C=CO1 Chemical compound CC1=C(C2=C(C3=CC=NC=C3)C3=NC=CN3C(N)=N2)C=CO1 WLEVMDSFOICAKH-UHFFFAOYSA-N 0.000 description 1
- KEQHPDQXCKWYAW-UHFFFAOYSA-N CC1=CC(C2=C(C3=CC4=C(CCC4)N=C3)N=C(N)N3C=CN=C23)=CC(C)=N1 Chemical compound CC1=CC(C2=C(C3=CC4=C(CCC4)N=C3)N=C(N)N3C=CN=C23)=CC(C)=N1 KEQHPDQXCKWYAW-UHFFFAOYSA-N 0.000 description 1
- PBLPKXFEYHVIOH-UHFFFAOYSA-N CC1=CC(C2=C(C3=CC=CC(C#N)=C3)N=C(N)N3C=CN=C23)=CC(C)=N1 Chemical compound CC1=CC(C2=C(C3=CC=CC(C#N)=C3)N=C(N)N3C=CN=C23)=CC(C)=N1 PBLPKXFEYHVIOH-UHFFFAOYSA-N 0.000 description 1
- VNFKWVFTHQYMID-UHFFFAOYSA-N CC1=CC(C2=C(C3=CC=CN=C3)N=C(N)N3C(CN4CCOCC4)=CN=C23)=CC(C)=N1 Chemical compound CC1=CC(C2=C(C3=CC=CN=C3)N=C(N)N3C(CN4CCOCC4)=CN=C23)=CC(C)=N1 VNFKWVFTHQYMID-UHFFFAOYSA-N 0.000 description 1
- XPZJHYJORRSWHH-UHFFFAOYSA-N CC1=CC(C2=C(Cl)N=C(N)N3C=CN=C23)=CC(C)=N1 Chemical compound CC1=CC(C2=C(Cl)N=C(N)N3C=CN=C23)=CC(C)=N1 XPZJHYJORRSWHH-UHFFFAOYSA-N 0.000 description 1
- WLUIVZSVMHVOQO-UHFFFAOYSA-N CC1=NC(CC(=O)NN)=CC=C1 Chemical compound CC1=NC(CC(=O)NN)=CC=C1 WLUIVZSVMHVOQO-UHFFFAOYSA-N 0.000 description 1
- BSXYBIGYCQOGAH-UHFFFAOYSA-N CC1=NC(CO)=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)O1 Chemical compound CC1=NC(CO)=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)O1 BSXYBIGYCQOGAH-UHFFFAOYSA-N 0.000 description 1
- WCQUAZLLKUQRRS-UHFFFAOYSA-N CC1=NC(CO)=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=NC=CC=C4F)N=C23)O1 Chemical compound CC1=NC(CO)=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=NC=CC=C4F)N=C23)O1 WCQUAZLLKUQRRS-UHFFFAOYSA-N 0.000 description 1
- KPOVHVIXAKFYNP-UHFFFAOYSA-N CC1=NC(COC2=NN3C(N)=NC(C4=CC=CC(C#N)=C4)=C(C4=NC=NC=C4)C3=N2)=CC=C1 Chemical compound CC1=NC(COC2=NN3C(N)=NC(C4=CC=CC(C#N)=C4)=C(C4=NC=NC=C4)C3=N2)=CC=C1 KPOVHVIXAKFYNP-UHFFFAOYSA-N 0.000 description 1
- VNVWOLFLPLCAQX-UHFFFAOYSA-N CC1=NC(CO[Si](C)(C)C(C)(C)C)=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)O1 Chemical compound CC1=NC(CO[Si](C)(C)C(C)(C)C)=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)O1 VNVWOLFLPLCAQX-UHFFFAOYSA-N 0.000 description 1
- NZKQXZRLUPGQAM-UHFFFAOYSA-N CC1=NC(CO[Si](C)(C)C(C)(C)C)=CO1 Chemical compound CC1=NC(CO[Si](C)(C)C(C)(C)C)=CO1 NZKQXZRLUPGQAM-UHFFFAOYSA-N 0.000 description 1
- JYPSIVQEYFCYTG-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(Cl)N3C=C(C4=CC=CC=C4)N=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(Cl)N3C=C(C4=CC=CC=C4)N=C23)=C1 JYPSIVQEYFCYTG-UHFFFAOYSA-N 0.000 description 1
- TVDALBVCWNWVAH-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=C(C(=O)O)N=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=C(C(=O)O)N=C23)=C1 TVDALBVCWNWVAH-UHFFFAOYSA-N 0.000 description 1
- IJASXFJZORORPF-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=C(C(N)=O)N=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=C(C(N)=O)N=C23)=C1 IJASXFJZORORPF-UHFFFAOYSA-N 0.000 description 1
- IIKKIGZBJWAIRX-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=C(C4=CC=CC=C4)N=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=C(C4=CC=CC=C4)N=C23)=C1 IIKKIGZBJWAIRX-UHFFFAOYSA-N 0.000 description 1
- FSBIEVWQMYAUNM-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=CN=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)N=C(N)N3C=CN=C23)=C1 FSBIEVWQMYAUNM-UHFFFAOYSA-N 0.000 description 1
- JBUNYTKSEMHZQO-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)NC(=O)N3C=C(C4=CC=CC=C4)N=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)NC(=O)N3C=C(C4=CC=CC=C4)N=C23)=C1 JBUNYTKSEMHZQO-UHFFFAOYSA-N 0.000 description 1
- DYMFSOCUDLBTBB-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CC=CC=C3)NC(=O)N3C=CN=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CC=CC=C3)NC(=O)N3C=CN=C23)=C1 DYMFSOCUDLBTBB-UHFFFAOYSA-N 0.000 description 1
- IJPNNRUVQFHIFE-UHFFFAOYSA-N CC1=NC=CC(C2=C(C3=CN(C)N=C3)N=C(N)N3C=CN=C23)=C1 Chemical compound CC1=NC=CC(C2=C(C3=CN(C)N=C3)N=C(N)N3C=CN=C23)=C1 IJPNNRUVQFHIFE-UHFFFAOYSA-N 0.000 description 1
- YDSSRJZVUDXSBL-UHFFFAOYSA-N CC1=NC=CC(C2=C(Cl)N=C(N)N3C=CN=C23)=C1 Chemical compound CC1=NC=CC(C2=C(Cl)N=C(N)N3C=CN=C23)=C1 YDSSRJZVUDXSBL-UHFFFAOYSA-N 0.000 description 1
- PHCFYKJMZNWLEG-UHFFFAOYSA-N CCC1=C(B2OC(C)(C)C(C)(C)O2)OC(C)=N1 Chemical compound CCC1=C(B2OC(C)(C)C(C)(C)O2)OC(C)=N1 PHCFYKJMZNWLEG-UHFFFAOYSA-N 0.000 description 1
- ZZKDGABMFBCSRP-UHFFFAOYSA-N CCC1=C(C)N=CC=C1 Chemical compound CCC1=C(C)N=CC=C1 ZZKDGABMFBCSRP-UHFFFAOYSA-N 0.000 description 1
- WVRWSSYZZQHUPS-UHFFFAOYSA-N CCCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2C=C(C(=O)NCC)N=C12 Chemical compound CCCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2C=C(C(=O)NCC)N=C12 WVRWSSYZZQHUPS-UHFFFAOYSA-N 0.000 description 1
- QCKBCYINTBGLPS-UHFFFAOYSA-N CCN1N=CC=C1C1=C(C2=CC(C#N)=CC=C2)N=C(N)N2N=C(C3(C4=CC=CC=C4)CC3)N=C12 Chemical compound CCN1N=CC=C1C1=C(C2=CC(C#N)=CC=C2)N=C(N)N2N=C(C3(C4=CC=CC=C4)CC3)N=C12 QCKBCYINTBGLPS-UHFFFAOYSA-N 0.000 description 1
- ZHKNDNJHSIMBEH-UHFFFAOYSA-N CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CC3=NN(C)C4=C3C=CC=C4)N=C12 Chemical compound CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CC3=NN(C)C4=C3C=CC=C4)N=C12 ZHKNDNJHSIMBEH-UHFFFAOYSA-N 0.000 description 1
- MLCQMJNAMHROBK-UHFFFAOYSA-N CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CC3=NOC4=C3C=CC=C4)N=C12 Chemical compound CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CC3=NOC4=C3C=CC=C4)N=C12 MLCQMJNAMHROBK-UHFFFAOYSA-N 0.000 description 1
- JXYNSTVWDZVCHC-UHFFFAOYSA-N CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CCl)N=C12 Chemical compound CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CCl)N=C12 JXYNSTVWDZVCHC-UHFFFAOYSA-N 0.000 description 1
- LKJUBNKJSYPMJP-UHFFFAOYSA-N CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CO)N=C12 Chemical compound CCN1N=CC=C1C1=C(C2=CC=CC(C#N)=C2)N=C(N)N2N=C(CO)N=C12 LKJUBNKJSYPMJP-UHFFFAOYSA-N 0.000 description 1
- KWOHPLZUUMRYAC-UHFFFAOYSA-N CCNC(=O)C1=C(Br)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 Chemical compound CCNC(=O)C1=C(Br)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 KWOHPLZUUMRYAC-UHFFFAOYSA-N 0.000 description 1
- XUMJDZLEUKISKG-UHFFFAOYSA-N CCNC(=O)C1=C(Br)N2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 Chemical compound CCNC(=O)C1=C(Br)N2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 XUMJDZLEUKISKG-UHFFFAOYSA-N 0.000 description 1
- PUHOETZEKRBPKX-UHFFFAOYSA-N CCNC(=O)C1=C(C)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 Chemical compound CCNC(=O)C1=C(C)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 PUHOETZEKRBPKX-UHFFFAOYSA-N 0.000 description 1
- DXKIHUZGUAVEHF-UHFFFAOYSA-N CCNC(=O)C1=C(C2=NC=CC=C2)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 Chemical compound CCNC(=O)C1=C(C2=NC=CC=C2)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 DXKIHUZGUAVEHF-UHFFFAOYSA-N 0.000 description 1
- DCLZZDUKBQABRJ-UHFFFAOYSA-N CCNC(=O)C1=C(OCCO)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 Chemical compound CCNC(=O)C1=C(OCCO)N2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 DCLZZDUKBQABRJ-UHFFFAOYSA-N 0.000 description 1
- VIAKHSAGNNVVJM-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=C(C)NN=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=C(C)NN=C3)C2=N1 VIAKHSAGNNVVJM-UHFFFAOYSA-N 0.000 description 1
- HHLOKXBOTKVWKQ-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=C4C=CC=CN4N=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=C4C=CC=CN4N=C3)C2=N1 HHLOKXBOTKVWKQ-UHFFFAOYSA-N 0.000 description 1
- GDTQYWYLFDVNGU-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=C4OCCOC4=NC=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=C4OCCOC4=NC=C3)C2=N1 GDTQYWYLFDVNGU-UHFFFAOYSA-N 0.000 description 1
- FJHMNSMSTGNOSS-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 FJHMNSMSTGNOSS-UHFFFAOYSA-N 0.000 description 1
- CXNKJNSOMQSKEL-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC=NN3C(C)C)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC=NN3C(C)C)C2=N1 CXNKJNSOMQSKEL-UHFFFAOYSA-N 0.000 description 1
- YPDKKXLRPITHDF-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC=NN3CC)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC=NN3CC)C2=N1 YPDKKXLRPITHDF-UHFFFAOYSA-N 0.000 description 1
- SBCRSXQUXQQCFU-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3CC3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(C3CC3)C2=N1 SBCRSXQUXQQCFU-UHFFFAOYSA-N 0.000 description 1
- OPPRRQKJFCEIOI-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 OPPRRQKJFCEIOI-UHFFFAOYSA-N 0.000 description 1
- XNVDKDGXAUNIRJ-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=[N+]([O-])C(C)=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=[N+]([O-])C(C)=C3)C2=N1 XNVDKDGXAUNIRJ-UHFFFAOYSA-N 0.000 description 1
- ZTSHAFVIBVMSTQ-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CCN(C(N)=O)CC3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CCN(C(N)=O)CC3)C2=N1 ZTSHAFVIBVMSTQ-UHFFFAOYSA-N 0.000 description 1
- LVVKOSFVVFOBQV-UHFFFAOYSA-N CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3CCN(C(N)=O)CC3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3CCN(C(N)=O)CC3)C2=N1 LVVKOSFVVFOBQV-UHFFFAOYSA-N 0.000 description 1
- NGVCANAVHADHLZ-UHFFFAOYSA-N CCNC(=O)C1=CN2C(NCC)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 Chemical compound CCNC(=O)C1=CN2C(NCC)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 NGVCANAVHADHLZ-UHFFFAOYSA-N 0.000 description 1
- QQIGYGGHOBQPEZ-UHFFFAOYSA-N CCNC(c(nc12)c[n]1c(N)nc(-c1cc(C#N)ccc1)c2-c1ccncc1F)=O Chemical compound CCNC(c(nc12)c[n]1c(N)nc(-c1cc(C#N)ccc1)c2-c1ccncc1F)=O QQIGYGGHOBQPEZ-UHFFFAOYSA-N 0.000 description 1
- LDFGSDNBUWIKAA-UHFFFAOYSA-N CCNC(c(nc12)c[n]1c(N)nc(-c1cc(C#N)ccc1)c2-c1ccncn1)=O Chemical compound CCNC(c(nc12)c[n]1c(N)nc(-c1cc(C#N)ccc1)c2-c1ccncn1)=O LDFGSDNBUWIKAA-UHFFFAOYSA-N 0.000 description 1
- MQWKCZDSLGSNNR-UHFFFAOYSA-N CCNC(c(nc12)c[n]1c(N)nc(-c1cc(C#N)ccc1)c2Br)=O Chemical compound CCNC(c(nc12)c[n]1c(N)nc(-c1cc(C#N)ccc1)c2Br)=O MQWKCZDSLGSNNR-UHFFFAOYSA-N 0.000 description 1
- OSWARBYINPTWQY-UHFFFAOYSA-N CCOC(=O)C1=CN2C(=N1)C(C1=CC(C)=[N+]([O-])C(C)=C1)=C(C1=CC=CC=C1)N=C2S(C)(=O)=O Chemical compound CCOC(=O)C1=CN2C(=N1)C(C1=CC(C)=[N+]([O-])C(C)=C1)=C(C1=CC=CC=C1)N=C2S(C)(=O)=O OSWARBYINPTWQY-UHFFFAOYSA-N 0.000 description 1
- TWTIQUFTDKNIRQ-UHFFFAOYSA-N CCOC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC=C3)C2=N1 Chemical compound CCOC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC=C3)C2=N1 TWTIQUFTDKNIRQ-UHFFFAOYSA-N 0.000 description 1
- VGKXVLXKEYTJBS-UHFFFAOYSA-N CCOC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=[N+]([O-])C(C)=C3)C2=N1 Chemical compound CCOC(=O)C1=CN2C(N)=NC(C3=CC=CC=C3)=C(C3=CC(C)=[N+]([O-])C(C)=C3)C2=N1 VGKXVLXKEYTJBS-UHFFFAOYSA-N 0.000 description 1
- CGMPXRAZZVPBQX-UHFFFAOYSA-N CCOC(=O)C1=CN2C(N)=NC(Cl)=CC2=N1 Chemical compound CCOC(=O)C1=CN2C(N)=NC(Cl)=CC2=N1 CGMPXRAZZVPBQX-UHFFFAOYSA-N 0.000 description 1
- JBLRAPIKOQDLAQ-UHFFFAOYSA-N CCOC(=O)C1=CN2C(NCC3=C(OC)C=C(OC)C=C3)=NC(C3=CC=CC=C3)=C(Br)C2=N1 Chemical compound CCOC(=O)C1=CN2C(NCC3=C(OC)C=C(OC)C=C3)=NC(C3=CC=CC=C3)=C(Br)C2=N1 JBLRAPIKOQDLAQ-UHFFFAOYSA-N 0.000 description 1
- NDOJNOAYIUOELO-UHFFFAOYSA-N CCOC(=O)C1=CN2C(NCC3=CC=C(OC)C=C3OC)=NC(C3=CC=CC(C#N)=C3)=C(Br)C2=N1 Chemical compound CCOC(=O)C1=CN2C(NCC3=CC=C(OC)C=C3OC)=NC(C3=CC=CC(C#N)=C3)=C(Br)C2=N1 NDOJNOAYIUOELO-UHFFFAOYSA-N 0.000 description 1
- OZPKXHBKVPRSKG-UHFFFAOYSA-N CCOC(=O)C1=CN2C(NCC3=CC=C(OC)C=C3OC)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 Chemical compound CCOC(=O)C1=CN2C(NCC3=CC=C(OC)C=C3OC)=NC(C3=CC=CC(C#N)=C3)=C(C3=CC(OC)=NC=C3)C2=N1 OZPKXHBKVPRSKG-UHFFFAOYSA-N 0.000 description 1
- YSAUHBSVNAVLCM-UHFFFAOYSA-N CCOC(=O)C1=CN2C(SC)=NC(C3=CC=CC(C#N)=C3)=C(Br)C2=N1 Chemical compound CCOC(=O)C1=CN2C(SC)=NC(C3=CC=CC(C#N)=C3)=C(Br)C2=N1 YSAUHBSVNAVLCM-UHFFFAOYSA-N 0.000 description 1
- NTNLLRAQVYGQPJ-UHFFFAOYSA-N CCOC(=O)C1=CN2C(SC)=NC(C3=CC=CC=C3)=C(Br)C2=N1 Chemical compound CCOC(=O)C1=CN2C(SC)=NC(C3=CC=CC=C3)=C(Br)C2=N1 NTNLLRAQVYGQPJ-UHFFFAOYSA-N 0.000 description 1
- NWTPYSKZAOEUAF-UHFFFAOYSA-N CCOC(=O)C1=CN2C(SC)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 Chemical compound CCOC(=O)C1=CN2C(SC)=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C2=N1 NWTPYSKZAOEUAF-UHFFFAOYSA-N 0.000 description 1
- PKPUWQRDTBLWDZ-UHFFFAOYSA-N CCOC(=O)C1=NN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(Br)C2=N1 Chemical compound CCOC(=O)C1=NN2C(N)=NC(C3=CC=CC(C#N)=C3)=C(Br)C2=N1 PKPUWQRDTBLWDZ-UHFFFAOYSA-N 0.000 description 1
- GJIDKFHUFBCLJO-UHFFFAOYSA-N CCOC(=O)C1=NOC(C2=CN3C(=O)NC(C4=CC=CC=C4)=C(C4=CC=NC=C4)C3=N2)=C1 Chemical compound CCOC(=O)C1=NOC(C2=CN3C(=O)NC(C4=CC=CC=C4)=C(C4=CC=NC=C4)C3=N2)=C1 GJIDKFHUFBCLJO-UHFFFAOYSA-N 0.000 description 1
- SPPKSKLLRNIEDS-UHFFFAOYSA-N CCOC(=O)C1=NOC(C2=CN3C(Cl)=NC(C4=CC=CC=C4)=C(C4=CC=NC=C4)C3=N2)=C1 Chemical compound CCOC(=O)C1=NOC(C2=CN3C(Cl)=NC(C4=CC=CC=C4)=C(C4=CC=NC=C4)C3=N2)=C1 SPPKSKLLRNIEDS-UHFFFAOYSA-N 0.000 description 1
- JCYXVQKKHHTTJK-UHFFFAOYSA-N CCOC(=O)CC1=C(CO[Si](C)(C)C(C)(C)C)C=CC=N1 Chemical compound CCOC(=O)CC1=C(CO[Si](C)(C)C(C)(C)C)C=CC=N1 JCYXVQKKHHTTJK-UHFFFAOYSA-N 0.000 description 1
- XIXVYSQESGYHQU-UHFFFAOYSA-N CCOC(=O)CC1=NC(C(F)(F)F)=CC=C1 Chemical compound CCOC(=O)CC1=NC(C(F)(F)F)=CC=C1 XIXVYSQESGYHQU-UHFFFAOYSA-N 0.000 description 1
- HCGQNENQYQTLDD-UHFFFAOYSA-N CCOC1=CC=C(C2=CN=C3C(C4=CC(C)=NC=C4)=C(C4=CC=CC=C4)N=C(N)N23)C=C1 Chemical compound CCOC1=CC=C(C2=CN=C3C(C4=CC(C)=NC=C4)=C(C4=CC=CC=C4)N=C(N)N23)C=C1 HCGQNENQYQTLDD-UHFFFAOYSA-N 0.000 description 1
- VYSVEUJDUPGQJZ-UHFFFAOYSA-N CC[n]1nccc1-c1c(-c2cc(C#N)ccc2)nc(N)[n]2nc(CC3CCCCC3)nc12 Chemical compound CC[n]1nccc1-c1c(-c2cc(C#N)ccc2)nc(N)[n]2nc(CC3CCCCC3)nc12 VYSVEUJDUPGQJZ-UHFFFAOYSA-N 0.000 description 1
- AZCDADRSNHPWAH-UHFFFAOYSA-N CCc1c(-c2c(-c3cc(C#N)ccc3)nc(N)[n]3nc(Cc4ccccn4)nc23)[o]cn1 Chemical compound CCc1c(-c2c(-c3cc(C#N)ccc3)nc(N)[n]3nc(Cc4ccccn4)nc23)[o]cn1 AZCDADRSNHPWAH-UHFFFAOYSA-N 0.000 description 1
- KCMHPIYXDPAKBC-UHFFFAOYSA-N CN(CC(N1Cc2cccc(F)c2Cc(nc23)n[n]2c(N)nc(-c2cccc(C#N)c2)c3-c2ccncn2)=O)C1=O Chemical compound CN(CC(N1Cc2cccc(F)c2Cc(nc23)n[n]2c(N)nc(-c2cccc(C#N)c2)c3-c2ccncn2)=O)C1=O KCMHPIYXDPAKBC-UHFFFAOYSA-N 0.000 description 1
- ZEMKYSGCMFDVHY-UHFFFAOYSA-N CN1C=CC(CC(=O)NN)=N1 Chemical compound CN1C=CC(CC(=O)NN)=N1 ZEMKYSGCMFDVHY-UHFFFAOYSA-N 0.000 description 1
- SCQJSULUCLHOFH-UHFFFAOYSA-N CN1C=CC(CC2=NN3C(N)=NC(C4=CC(C#N)=CC=C4)=C(Br)C3=N2)=N1 Chemical compound CN1C=CC(CC2=NN3C(N)=NC(C4=CC(C#N)=CC=C4)=C(Br)C3=N2)=N1 SCQJSULUCLHOFH-UHFFFAOYSA-N 0.000 description 1
- BUYBHIBILZRJJN-UHFFFAOYSA-N CN1C=CC(CC2=NN3C(N)=NC(C4=CC(C#N)=CC=C4)=C(C4=CN=CO4)C3=N2)=N1 Chemical compound CN1C=CC(CC2=NN3C(N)=NC(C4=CC(C#N)=CC=C4)=C(C4=CN=CO4)C3=N2)=N1 BUYBHIBILZRJJN-UHFFFAOYSA-N 0.000 description 1
- SNDQKHJTIYPYTI-UHFFFAOYSA-N CN1C=CC(CC2=NN3C(N)=NC(C4=CC(C#N)=CC=C4)=CC3=N2)=N1 Chemical compound CN1C=CC(CC2=NN3C(N)=NC(C4=CC(C#N)=CC=C4)=CC3=N2)=N1 SNDQKHJTIYPYTI-UHFFFAOYSA-N 0.000 description 1
- BFFADXIYYTUCTC-UHFFFAOYSA-N COC(=O)C(O)C1=C(F)C=CC=C1F Chemical compound COC(=O)C(O)C1=C(F)C=CC=C1F BFFADXIYYTUCTC-UHFFFAOYSA-N 0.000 description 1
- FWGGFOAIYLYSHG-UHFFFAOYSA-N COC(=O)C1=NOC(C2=CN3C(N)=NC(C4=CC=CC=C4)=C(C4=CC=NC=C4)C3=N2)=C1 Chemical compound COC(=O)C1=NOC(C2=CN3C(N)=NC(C4=CC=CC=C4)=C(C4=CC=NC=C4)C3=N2)=C1 FWGGFOAIYLYSHG-UHFFFAOYSA-N 0.000 description 1
- GIFRTTRBMQQKRD-UHFFFAOYSA-N COC(=O)CC1=NN(C)C=C1 Chemical compound COC(=O)CC1=NN(C)C=C1 GIFRTTRBMQQKRD-UHFFFAOYSA-N 0.000 description 1
- HMOUQWHHEDSFNY-UHFFFAOYSA-N COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=C(Br)C3=NC(N)=NN32)C=C1 Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=C(Br)C3=NC(N)=NN32)C=C1 HMOUQWHHEDSFNY-UHFFFAOYSA-N 0.000 description 1
- YGOUBWBLEAIGIQ-UHFFFAOYSA-N COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=C(C3=NC=NC=C3)C3=NC(Br)=NN32)C=C1 Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=C(C3=NC=NC=C3)C3=NC(Br)=NN32)C=C1 YGOUBWBLEAIGIQ-UHFFFAOYSA-N 0.000 description 1
- IKIDODGPSYEVMV-UHFFFAOYSA-N COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=C(C3=NC=NC=C3)C3=NC(N)=NN32)C=C1 Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=C(C3=NC=NC=C3)C3=NC(N)=NN32)C=C1 IKIDODGPSYEVMV-UHFFFAOYSA-N 0.000 description 1
- AGDJPNVUNGHDOB-UHFFFAOYSA-N COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=CC3=NC(N)=NN32)C=C1 Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(C3=CC=CC(C#N)=C3)=CC3=NC(N)=NN32)C=C1 AGDJPNVUNGHDOB-UHFFFAOYSA-N 0.000 description 1
- BMXCIOSRIOTOJA-UHFFFAOYSA-N COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(Cl)=CC(N)=N2)C=C1 Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(Cl)=CC(N)=N2)C=C1 BMXCIOSRIOTOJA-UHFFFAOYSA-N 0.000 description 1
- QIJMCQBYTWCTCL-UHFFFAOYSA-N COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(Cl)=CC3=NC(N)=NN32)C=C1 Chemical compound COC1=CC=C(CN(CC2=CC=C(OC)C=C2)C2=NC(Cl)=CC3=NC(N)=NN32)C=C1 QIJMCQBYTWCTCL-UHFFFAOYSA-N 0.000 description 1
- XDNCKYHVWFRVCG-UHFFFAOYSA-N COC1=CC=C(CNC2=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C3=NC(C(=O)O)=CN23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC(C3=CC=CC=C3)=C(C3=CC(C)=NC(C)=C3)C3=NC(C(=O)O)=CN23)C(OC)=C1 XDNCKYHVWFRVCG-UHFFFAOYSA-N 0.000 description 1
- KOTRBKQRHIWPEW-UHFFFAOYSA-N COC1=NC(C)=CC(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)=C1 Chemical compound COC1=NC(C)=CC(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)=C1 KOTRBKQRHIWPEW-UHFFFAOYSA-N 0.000 description 1
- CYTAQHJYRSFCQV-UHFFFAOYSA-N COC1=NC(C2=CC=CC=C2)=C(C2=CC(C)=NC=C2)C(N)=N1 Chemical compound COC1=NC(C2=CC=CC=C2)=C(C2=CC(C)=NC=C2)C(N)=N1 CYTAQHJYRSFCQV-UHFFFAOYSA-N 0.000 description 1
- DVJJWXUBWTZUTR-UHFFFAOYSA-N COC1=NC(C2=CC=CC=C2)=CC(N)=N1 Chemical compound COC1=NC(C2=CC=CC=C2)=CC(N)=N1 DVJJWXUBWTZUTR-UHFFFAOYSA-N 0.000 description 1
- IXXYQIOTEAKBMM-UHFFFAOYSA-N COCC1=C(B2OC(C)(C)C(C)(C)O2)OC(C)=N1 Chemical compound COCC1=C(B2OC(C)(C)C(C)(C)O2)OC(C)=N1 IXXYQIOTEAKBMM-UHFFFAOYSA-N 0.000 description 1
- AUVITSIYJLPWLX-UHFFFAOYSA-N COCC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)OC(C)=N1 Chemical compound COCC1=C(C2=C(C3=CC(C#N)=CC=C3)N=C(N)N3N=C(CC4=CC=CC=N4)N=C23)OC(C)=N1 AUVITSIYJLPWLX-UHFFFAOYSA-N 0.000 description 1
- ASEMKYZYKICICV-UHFFFAOYSA-N COCC1=COC(C)=N1 Chemical compound COCC1=COC(C)=N1 ASEMKYZYKICICV-UHFFFAOYSA-N 0.000 description 1
- ZFYYNZUIFAWSHR-UHFFFAOYSA-N CSC1=NC(C2=CC=CC=C2)=C(C2=CC(C)=NC(C)=C2)C(N)=N1 Chemical compound CSC1=NC(C2=CC=CC=C2)=C(C2=CC(C)=NC(C)=C2)C(N)=N1 ZFYYNZUIFAWSHR-UHFFFAOYSA-N 0.000 description 1
- ZNNBEXKNOPBQDC-UHFFFAOYSA-N CSC1=NC(N)=C(Br)C(C2=CC=CC(C#N)=C2)=N1 Chemical compound CSC1=NC(N)=C(Br)C(C2=CC=CC(C#N)=C2)=N1 ZNNBEXKNOPBQDC-UHFFFAOYSA-N 0.000 description 1
- QGGIRLHCJLRWRI-UHFFFAOYSA-N CSC1=NC(N)=C(Br)C(C2=CC=CC=C2)=N1 Chemical compound CSC1=NC(N)=C(Br)C(C2=CC=CC=C2)=N1 QGGIRLHCJLRWRI-UHFFFAOYSA-N 0.000 description 1
- OECBKFQJHQFMJA-UHFFFAOYSA-N CSC1=NC(N)=CC(C2=CC=CC(C#N)=C2)=N1 Chemical compound CSC1=NC(N)=CC(C2=CC=CC(C#N)=C2)=N1 OECBKFQJHQFMJA-UHFFFAOYSA-N 0.000 description 1
- UUTMXCYCFJHKOB-UHFFFAOYSA-N CSC1=NC(N)=CC(C2=CC=CC=C2)=N1 Chemical compound CSC1=NC(N)=CC(C2=CC=CC=C2)=N1 UUTMXCYCFJHKOB-UHFFFAOYSA-N 0.000 description 1
- DSQMTHPMYGTYQN-UHFFFAOYSA-N C[Sn](C)(C)C1=NC=NC=C1F Chemical compound C[Sn](C)(C)C1=NC=NC=C1F DSQMTHPMYGTYQN-UHFFFAOYSA-N 0.000 description 1
- BBUINXQIQVRGNO-UHFFFAOYSA-N N#CC1=CC(C2=C(Br)C3=NC(CC4=NOC5=C4C=CC=C5)=NN3C(N)=N2)=CC=C1 Chemical compound N#CC1=CC(C2=C(Br)C3=NC(CC4=NOC5=C4C=CC=C5)=NN3C(N)=N2)=CC=C1 BBUINXQIQVRGNO-UHFFFAOYSA-N 0.000 description 1
- MSCXSCAODWWPRA-UHFFFAOYSA-N N#CC1=CC(C2=C(Br)C3=NC(CO)=NN3C(N)=N2)=CC=C1 Chemical compound N#CC1=CC(C2=C(Br)C3=NC(CO)=NN3C(N)=N2)=CC=C1 MSCXSCAODWWPRA-UHFFFAOYSA-N 0.000 description 1
- QJLCTFZMTFDCKB-UHFFFAOYSA-N N#CC1=CC(C2=C(C3=CC=NC=N3)C3=NC(CN4CC(O)C4)=NN3C(N)=N2)=CC=C1 Chemical compound N#CC1=CC(C2=C(C3=CC=NC=N3)C3=NC(CN4CC(O)C4)=NN3C(N)=N2)=CC=C1 QJLCTFZMTFDCKB-UHFFFAOYSA-N 0.000 description 1
- ISUADZJWVFVIAM-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(Br)C3=NC(C(O)C4=CC=CC=C4)=NN3C(NC3=NC=CC=C3C#N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(Br)C3=NC(C(O)C4=CC=CC=C4)=NN3C(NC3=NC=CC=C3C#N)=N2)=C1 ISUADZJWVFVIAM-UHFFFAOYSA-N 0.000 description 1
- VQFDOMMGWBVSEV-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(Br)C3=NC(C4(C5=CC=CC=C5)CC4)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(Br)C3=NC(C4(C5=CC=CC=C5)CC4)=NN3C(N)=N2)=C1 VQFDOMMGWBVSEV-UHFFFAOYSA-N 0.000 description 1
- VMGFCHNTUJKGTN-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(C3=C4C=CC=NN4N=C3)C3=NC(CC4=CC=CC=N4)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=C4C=CC=NN4N=C3)C3=NC(CC4=CC=CC=N4)=NN3C(N)=N2)=C1 VMGFCHNTUJKGTN-UHFFFAOYSA-N 0.000 description 1
- LUZZXOOFSMMZCH-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(=O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(=O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 LUZZXOOFSMMZCH-UHFFFAOYSA-N 0.000 description 1
- RROKBRXRMOPJBA-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(O)C4=CC=CC=C4)=NN3C(NC3=NC=CC=C3C#N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(O)C4=CC=CC=C4)=NN3C(NC3=NC=CC=C3C#N)=N2)=C1 RROKBRXRMOPJBA-UHFFFAOYSA-N 0.000 description 1
- HTJQDORPWAPVSB-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CO)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CO)=NN3C(N)=N2)=C1 HTJQDORPWAPVSB-UHFFFAOYSA-N 0.000 description 1
- VYMAQPYIBOACPX-UHFFFAOYSA-N N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(NC(C#N)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(NC(C#N)C4=CC=CC=C4)=NN3C(N)=N2)=C1 VYMAQPYIBOACPX-UHFFFAOYSA-N 0.000 description 1
- IRSRAYLJTCRMGF-ZCLATKBISA-N N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC([C@@H](O)C4=CC=CC=C4)=NN3C(N)=N2)=C1.N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC([C@H](O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC([C@@H](O)C4=CC=CC=C4)=NN3C(N)=N2)=C1.N#CC1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC([C@H](O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 IRSRAYLJTCRMGF-ZCLATKBISA-N 0.000 description 1
- MOGZBALEYNVQRZ-UHFFFAOYSA-N N#CC1=CC=CC(C2=CC3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=CC3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 MOGZBALEYNVQRZ-UHFFFAOYSA-N 0.000 description 1
- QSEHXGVWWFMRMZ-UHFFFAOYSA-N N#CC1=CC=CC(C2=CC3=NC(CO)=NN3C(N)=N2)=C1 Chemical compound N#CC1=CC=CC(C2=CC3=NC(CO)=NN3C(N)=N2)=C1 QSEHXGVWWFMRMZ-UHFFFAOYSA-N 0.000 description 1
- CGGRWSNAKPBNEG-UHFFFAOYSA-N NC1=NC(C2=CC3=C(C=CC=C3)O2)=C(C2=CC=NC=C2)C2=NC=CN12 Chemical compound NC1=NC(C2=CC3=C(C=CC=C3)O2)=C(C2=CC=NC=C2)C2=NC=CN12 CGGRWSNAKPBNEG-UHFFFAOYSA-N 0.000 description 1
- QNXGTKDUQGDBPT-UHFFFAOYSA-N NC1=NC(C2=CC=CC=C2F)=C(C2=CC=NC=C2)C2=NC=CN12 Chemical compound NC1=NC(C2=CC=CC=C2F)=C(C2=CC=NC=C2)C2=NC=CN12 QNXGTKDUQGDBPT-UHFFFAOYSA-N 0.000 description 1
- OFCAFXOFQQZGNF-UHFFFAOYSA-N NC1=NC(C2=CC=NC=C2)=C(C2=CC=NC=C2)C2=NC=CN12 Chemical compound NC1=NC(C2=CC=NC=C2)=C(C2=CC=NC=C2)C2=NC=CN12 OFCAFXOFQQZGNF-UHFFFAOYSA-N 0.000 description 1
- JZDZZIXETBDPOB-UHFFFAOYSA-N NC1=NC(Cl)=C(Br)C2=NC=CN12 Chemical compound NC1=NC(Cl)=C(Br)C2=NC=CN12 JZDZZIXETBDPOB-UHFFFAOYSA-N 0.000 description 1
- XBTHOTVRUMBOMO-UHFFFAOYSA-N NC1=NC(Cl)=NC(Cl)=C1Br Chemical compound NC1=NC(Cl)=NC(Cl)=C1Br XBTHOTVRUMBOMO-UHFFFAOYSA-N 0.000 description 1
- NRPAJWLZXPNDOY-UHFFFAOYSA-N NNC(=O)CC1=CC=CC=N1 Chemical compound NNC(=O)CC1=CC=CC=N1 NRPAJWLZXPNDOY-UHFFFAOYSA-N 0.000 description 1
- FDDWZOFJTMLWRV-UHFFFAOYSA-N NNC(=O)CC1=NC=CC=C1F Chemical compound NNC(=O)CC1=NC=CC=C1F FDDWZOFJTMLWRV-UHFFFAOYSA-N 0.000 description 1
- KIAXAABMMWEBRS-UHFFFAOYSA-N Nc([n]1nc(C(c2ccccc2)Oc2ccccn2)nc11)nc(-c2cc(C#N)ccc2)c1Br Chemical compound Nc([n]1nc(C(c2ccccc2)Oc2ccccn2)nc11)nc(-c2cc(C#N)ccc2)c1Br KIAXAABMMWEBRS-UHFFFAOYSA-N 0.000 description 1
- FBUFJQGAFJKAJJ-UHFFFAOYSA-N Nc([n]1nc(C[n]2nnnc2-c2ccccn2)nc11)nc(-c2cc(C#N)ccc2)c1-c1ccncn1 Chemical compound Nc([n]1nc(C[n]2nnnc2-c2ccccn2)nc11)nc(-c2cc(C#N)ccc2)c1-c1ccncn1 FBUFJQGAFJKAJJ-UHFFFAOYSA-N 0.000 description 1
- NWCMFGNOKXKAAW-UHFFFAOYSA-N Nc([n]1nc(Cc2ccccn2)nc11)nc(-c2cc(C#N)ccc2)c1Br Chemical compound Nc([n]1nc(Cc2ccccn2)nc11)nc(-c2cc(C#N)ccc2)c1Br NWCMFGNOKXKAAW-UHFFFAOYSA-N 0.000 description 1
- QRWFZOKRPJVZSF-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(=O)N4CC(O)C4)=CN3C(NCC3=C(OC)C=C(OC)C=C3)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(=O)N4CC(O)C4)=CN3C(NCC3=C(OC)C=C(OC)C=C3)=N2)=CC=C1 QRWFZOKRPJVZSF-UHFFFAOYSA-N 0.000 description 1
- PVTUVCOQPGUOPD-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 PVTUVCOQPGUOPD-UHFFFAOYSA-N 0.000 description 1
- XZRXMZORENJMOC-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(=O)OCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(=O)OCC)=CN3C(N)=N2)=CC=C1 XZRXMZORENJMOC-UHFFFAOYSA-N 0.000 description 1
- JUVNEQIIWCDQRJ-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(OC4=NC=CC=C4)C4=CC=CC=C4)=NN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C(OC4=NC=CC=C4)C4=CC=CC=C4)=NN3C(N)=N2)=CC=C1 JUVNEQIIWCDQRJ-UHFFFAOYSA-N 0.000 description 1
- BEYVRRUZPMZIFJ-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C4CCOC4)=NN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(Br)C3=NC(C4CCOC4)=NN3C(N)=N2)=CC=C1 BEYVRRUZPMZIFJ-UHFFFAOYSA-N 0.000 description 1
- RFANEXJCPFDOMB-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=C(C#N)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=C(C#N)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 RFANEXJCPFDOMB-UHFFFAOYSA-N 0.000 description 1
- OQLKNLMPERAKEJ-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=C(C)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=C(C)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 OQLKNLMPERAKEJ-UHFFFAOYSA-N 0.000 description 1
- KWWPHTXWOAKKFS-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=C(Cl)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=C(Cl)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 KWWPHTXWOAKKFS-UHFFFAOYSA-N 0.000 description 1
- KGXMKAOFGIHKHT-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=C(F)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=C(F)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 KGXMKAOFGIHKHT-UHFFFAOYSA-N 0.000 description 1
- GJHXLGHONVAPDC-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=C(OC)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=C(OC)C=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 GJHXLGHONVAPDC-UHFFFAOYSA-N 0.000 description 1
- WOLDAERLBJMRCU-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=CC=C(C(N)=O)C=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=CC=C(C(N)=O)C=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 WOLDAERLBJMRCU-UHFFFAOYSA-N 0.000 description 1
- QDZNRWABUZZLPW-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=CC=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=CC=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 QDZNRWABUZZLPW-UHFFFAOYSA-N 0.000 description 1
- IAWVBKGVQDBPAY-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=CC=NC=C3)C3=NC(C4CCOC4)=NN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=CC=NC=C3)C3=NC(C4CCOC4)=NN3C(N)=N2)=CC=C1 IAWVBKGVQDBPAY-UHFFFAOYSA-N 0.000 description 1
- OQFNDQFCKIPXNM-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=CN(CC)C(=O)C=C3)C3=NC(C(=O)N4CC(O)C4)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=CN(CC)C(=O)C=C3)C3=NC(C(=O)N4CC(O)C4)=CN3C(N)=N2)=CC=C1 OQFNDQFCKIPXNM-UHFFFAOYSA-N 0.000 description 1
- FYVBDVIHSIUQGL-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=CN(CC)C(=O)C=C3)C3=NC(C(=O)NC4=CN(CCO)N=C4)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=CN(CC)C(=O)C=C3)C3=NC(C(=O)NC4=CN(CCO)N=C4)=CN3C(N)=N2)=CC=C1 FYVBDVIHSIUQGL-UHFFFAOYSA-N 0.000 description 1
- BIQBBTXCTVWSEM-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=NC=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=NC=NC=C3)C3=NC(C(=O)NCC)=CN3C(N)=N2)=CC=C1 BIQBBTXCTVWSEM-UHFFFAOYSA-N 0.000 description 1
- NAZYISRLCUZLEH-UHFFFAOYSA-N [C-]#[N+]C1=CC(C2=C(C3=NC=NC=C3)C3=NC(C(OC4=NC=CC=C4)C4=CC=CC=C4)=NN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=NC=NC=C3)C3=NC(C(OC4=NC=CC=C4)C4=CC=CC=C4)=NN3C(N)=N2)=CC=C1 NAZYISRLCUZLEH-UHFFFAOYSA-N 0.000 description 1
- OYWWHNQWAMZIDW-FYYLOGMGSA-N [C-]#[N+]C1=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(CN5C[C@@H](O)[C@H](F)C5)C=CC=C4F)=NN3C(N)=N2)=CC=C1 Chemical compound [C-]#[N+]C1=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(CN5C[C@@H](O)[C@H](F)C5)C=CC=C4F)=NN3C(N)=N2)=CC=C1 OYWWHNQWAMZIDW-FYYLOGMGSA-N 0.000 description 1
- XDPLFQSOQJOAFS-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(C(Cl)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(C(Cl)C4=CC=CC=C4)=NN3C(N)=N2)=C1 XDPLFQSOQJOAFS-UHFFFAOYSA-N 0.000 description 1
- SXKCIJFBNUDLMD-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(C(NCCO)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(C(NCCO)C4=CC=CC=C4)=NN3C(N)=N2)=C1 SXKCIJFBNUDLMD-UHFFFAOYSA-N 0.000 description 1
- JBQZDCLNIBTDAL-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(C(O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(C(O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 JBQZDCLNIBTDAL-UHFFFAOYSA-N 0.000 description 1
- CPSBUFPBBITFPF-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=C(C)C=CC=N4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=C(C)C=CC=N4)=NN3C(N)=N2)=C1 CPSBUFPBBITFPF-UHFFFAOYSA-N 0.000 description 1
- IREXXRQHWYVXOF-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=C(CO)C=CC=N4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=C(CO)C=CC=N4)=NN3C(N)=N2)=C1 IREXXRQHWYVXOF-UHFFFAOYSA-N 0.000 description 1
- RLJLHADIKNUFQF-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC(C(F)(F)F)=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC(C(F)(F)F)=CC=C4)=NN3C(N)=N2)=C1 RLJLHADIKNUFQF-UHFFFAOYSA-N 0.000 description 1
- JLBOTPWMWHTIIJ-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 JLBOTPWMWHTIIJ-UHFFFAOYSA-N 0.000 description 1
- DVQIVLLPOXPECA-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1F Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1F DVQIVLLPOXPECA-UHFFFAOYSA-N 0.000 description 1
- QUSHNSQRBIBXFT-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC=CC=C4F)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4=NC=CC=C4F)=NN3C(N)=N2)=C1 QUSHNSQRBIBXFT-UHFFFAOYSA-N 0.000 description 1
- YWCYZYXLRKFCEL-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4CCCCC4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CC4CCCCC4)=NN3C(N)=N2)=C1 YWCYZYXLRKFCEL-UHFFFAOYSA-N 0.000 description 1
- GMFVJGHYTYSLFR-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CO)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(Br)C3=NC(CO)=NN3C(N)=N2)=C1 GMFVJGHYTYSLFR-UHFFFAOYSA-N 0.000 description 1
- WPXWPAAJBWLXHL-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=C(C)N=CO3)C3=NC(CC4=NC(C(F)(F)F)=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=C(C)N=CO3)C3=NC(CC4=NC(C(F)(F)F)=CC=C4)=NN3C(N)=N2)=C1 WPXWPAAJBWLXHL-UHFFFAOYSA-N 0.000 description 1
- GSUKCBWYKTZXGE-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=C(C)N=CO3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1F Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=C(C)N=CO3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1F GSUKCBWYKTZXGE-UHFFFAOYSA-N 0.000 description 1
- ZTXXJXRNOBDEKU-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=C(C)N=CO3)C3=NC(CC4=NC=CC=C4CO)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=C(C)N=CO3)C3=NC(CC4=NC=CC=C4CO)=NN3C(N)=N2)=C1 ZTXXJXRNOBDEKU-UHFFFAOYSA-N 0.000 description 1
- AFQTWDGTSITTNR-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=C(CC)N=CO3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=C(CC)N=CO3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 AFQTWDGTSITTNR-UHFFFAOYSA-N 0.000 description 1
- IBOVJXGGWPRIIS-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=C(CC)N=CO3)C3=NC(CC4=NC=CC=C4C)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=C(CC)N=CO3)C3=NC(CC4=NC=CC=C4C)=NN3C(N)=N2)=C1 IBOVJXGGWPRIIS-UHFFFAOYSA-N 0.000 description 1
- UUPAWZUWKOAFMG-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=C4C=CC=NC4=CC=C3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=C4C=CC=NC4=CC=C3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 UUPAWZUWKOAFMG-UHFFFAOYSA-N 0.000 description 1
- LEZBQJKHLWAMNB-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NC=C3)C3=NC(C(NCCO)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NC=C3)C3=NC(C(NCCO)C4=CC=CC=C4)=NN3C(N)=N2)=C1 LEZBQJKHLWAMNB-UHFFFAOYSA-N 0.000 description 1
- IARVADSJGCUMIP-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NC=N3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NC=N3)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 IARVADSJGCUMIP-UHFFFAOYSA-N 0.000 description 1
- RCTTXNPWYPGNGE-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 RCTTXNPWYPGNGE-UHFFFAOYSA-N 0.000 description 1
- XDWKWWHOGIWDRO-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4=NC=CC=C4F)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4=NC=CC=C4F)=NN3C(N)=N2)=C1 XDWKWWHOGIWDRO-UHFFFAOYSA-N 0.000 description 1
- GMSFKXRPDMDYLW-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4=NC=CC=C4OC)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4=NC=CC=C4OC)=NN3C(N)=N2)=C1 GMSFKXRPDMDYLW-UHFFFAOYSA-N 0.000 description 1
- AERJLLDTHLRVOP-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4CCCCC4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CC)C3=NC(CC4CCCCC4)=NN3C(N)=N2)=C1 AERJLLDTHLRVOP-UHFFFAOYSA-N 0.000 description 1
- OHBMZQNXYDFKNO-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CCC)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CC=NN3CCC)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 OHBMZQNXYDFKNO-UHFFFAOYSA-N 0.000 description 1
- WEONDJVLOLAYRE-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=CN=NN3CC)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=CN=NN3CC)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 WEONDJVLOLAYRE-UHFFFAOYSA-N 0.000 description 1
- UVNNGIHSPKHWSL-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(O)C4=C(F)C=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(C(O)C4=C(F)C=CC=C4)=NN3C(N)=N2)=C1 UVNNGIHSPKHWSL-UHFFFAOYSA-N 0.000 description 1
- DITWHGNGRPVMTQ-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(Br)C=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(Br)C=CC=C4)=NN3C(N)=N2)=C1 DITWHGNGRPVMTQ-UHFFFAOYSA-N 0.000 description 1
- DOCOADCURXCYQO-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(C5=CN(C)N=C5)C=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(C5=CN(C)N=C5)C=CC=C4)=NN3C(N)=N2)=C1 DOCOADCURXCYQO-UHFFFAOYSA-N 0.000 description 1
- KVSIDYHFLLCIAC-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4)=NN3C(N)=N2)=C1 KVSIDYHFLLCIAC-UHFFFAOYSA-N 0.000 description 1
- VBSIZZQFEZWBNM-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CCl)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CCl)=NN3C(N)=N2)=C1 VBSIZZQFEZWBNM-UHFFFAOYSA-N 0.000 description 1
- SWYONRUYGBZHGG-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN(C)S(C)(=O)=O)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN(C)S(C)(=O)=O)=NN3C(N)=N2)=C1 SWYONRUYGBZHGG-UHFFFAOYSA-N 0.000 description 1
- YXZFEFDXIKVTPB-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4C(=O)CN(C)C4=O)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4C(=O)CN(C)C4=O)=NN3C(N)=N2)=C1 YXZFEFDXIKVTPB-UHFFFAOYSA-N 0.000 description 1
- ATLZUEXYSKOUNJ-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4C(=O)CNC4=O)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4C(=O)CNC4=O)=NN3C(N)=N2)=C1 ATLZUEXYSKOUNJ-UHFFFAOYSA-N 0.000 description 1
- PHJUQPYDXKHYLB-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4CCC(C(=O)O)CC4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4CCC(C(=O)O)CC4)=NN3C(N)=N2)=C1 PHJUQPYDXKHYLB-UHFFFAOYSA-N 0.000 description 1
- YYGMXQVRAIVWAO-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4CCC(C(=O)OC)CC4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4CCC(C(=O)OC)CC4)=NN3C(N)=N2)=C1 YYGMXQVRAIVWAO-UHFFFAOYSA-N 0.000 description 1
- YJXDZYCCFRETOB-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4CCCS4(=O)=O)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CN4CCCS4(=O)=O)=NN3C(N)=N2)=C1 YJXDZYCCFRETOB-UHFFFAOYSA-N 0.000 description 1
- KRCNDKITSUTXCN-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CO)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=C(F)C=CC=C4CO)=NN3C(N)=N2)=C1 KRCNDKITSUTXCN-UHFFFAOYSA-N 0.000 description 1
- KBWSLTNSKDPNFB-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=NC(C)=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=NC(C)=CC=C4)=NN3C(N)=N2)=C1 KBWSLTNSKDPNFB-UHFFFAOYSA-N 0.000 description 1
- CJVFCXMFAAFFKH-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=NC=CC=C4F)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CC4=NC=CC=C4F)=NN3C(N)=N2)=C1 CJVFCXMFAAFFKH-UHFFFAOYSA-N 0.000 description 1
- MJXDQRZDXFZJNR-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CCl)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CCl)=NN3C(N)=N2)=C1 MJXDQRZDXFZJNR-UHFFFAOYSA-N 0.000 description 1
- AFIPFWKGMVKNCS-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=C(C(F)(F)F)C=C4C)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=C(C(F)(F)F)C=C4C)=NN3C(N)=N2)=C1 AFIPFWKGMVKNCS-UHFFFAOYSA-N 0.000 description 1
- UESHGGHLDIHKHT-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=NN=C4C4=CSC=N4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=NN=C4C4=CSC=N4)=NN3C(N)=N2)=C1 UESHGGHLDIHKHT-UHFFFAOYSA-N 0.000 description 1
- SJQIMUFVOWTERW-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=NN=C4C4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=NN=C4C4=NC=CC=C4)=NN3C(N)=N2)=C1 SJQIMUFVOWTERW-UHFFFAOYSA-N 0.000 description 1
- IIOJAMYFRPVMCG-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=NN=C4N4C=CC=N4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CN4N=NN=C4N4C=CC=N4)=NN3C(N)=N2)=C1 IIOJAMYFRPVMCG-UHFFFAOYSA-N 0.000 description 1
- XDUUQTVFZXWWRT-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CO)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3)C3=NC(CO)=NN3C(N)=N2)=C1 XDUUQTVFZXWWRT-UHFFFAOYSA-N 0.000 description 1
- QRKSSZJMKWNSKG-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3F)C3=NC(C(O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3F)C3=NC(C(O)C4=CC=CC=C4)=NN3C(N)=N2)=C1 QRKSSZJMKWNSKG-UHFFFAOYSA-N 0.000 description 1
- QEZRXVMBBXIICC-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3F)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(C3=NC=NC=C3F)C3=NC(CC4=NC=CC=C4)=NN3C(N)=N2)=C1 QEZRXVMBBXIICC-UHFFFAOYSA-N 0.000 description 1
- PARHTCZDQIUDFU-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=C(I)C3=NC(CC4=C(Br)C=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=C(I)C3=NC(CC4=C(Br)C=CC=C4)=NN3C(N)=N2)=C1 PARHTCZDQIUDFU-UHFFFAOYSA-N 0.000 description 1
- PGORLGVHIZZQLL-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=CC(Cl)=NC(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=CC(Cl)=NC(N)=N2)=C1 PGORLGVHIZZQLL-UHFFFAOYSA-N 0.000 description 1
- XDVZRBDEQOVUSW-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=CC3=NC(CC4=C(Br)C=CC=C4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=CC3=NC(CC4=C(Br)C=CC=C4)=NN3C(N)=N2)=C1 XDVZRBDEQOVUSW-UHFFFAOYSA-N 0.000 description 1
- LVETWZFHCGNGJX-UHFFFAOYSA-N [C-]#[N+]C1=CC=CC(C2=CC3=NC(CC4=C(CO)C=CC=N4)=NN3C(N)=N2)=C1 Chemical compound [C-]#[N+]C1=CC=CC(C2=CC3=NC(CC4=C(CO)C=CC=N4)=NN3C(N)=N2)=C1 LVETWZFHCGNGJX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- each R f4 and R g4 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R f2 , R g2 , R f3 , and R g3 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R a6 , R c6 , and R d6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycl
- each R j6 and R k6 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- each R b7 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-,
- each R j7 and R k7 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- Cy 1 is C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R E substituents;
- each R f2 , R g2 , R f3 , and R g3 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j2 , R k2 , R j3 , and R k3 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- R j2 and R k2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl;
- each R B , R C , R D , R E , R F , and R G is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a4 , SR a4 , NHOR a4 , C(O)R b4 , C(O)NR c4 R d4 , C(O)NR c4 (OR a4 ), C(O)
- each R e4 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R j4 and R k4 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- each R H is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a5 , SR a5 , NHOR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)NR c5 (OR a5 ), C(O)OR a5 , OC(O)R b5 , OC(O
- R c7 and R d7 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
- each R h2 , R i2 , R h3 , and R i3 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R b4 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-,
- each R H is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a5 , SR a5 , NHOR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)NR c5 (OR a5 ), C(O)OR a5 , OC(O)R b5 , OC(O
- each R a5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycl
- each R I is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a6 , SR a6 , NHOR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)NR c6 (OR a6 ), C(O)OR a6 , OC(O)R b6 , OC(
- X is N
- each R b6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-,
- X is N
- R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
- each R J is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, CN, NO 2 , OR a7 , SR a7 , NHOR a7 , C(O)R b7 , C(O)NR c7 R d7 , C(O)NR c7 (OR a7 ), C(O)OR a7 , OC(O)R b7 , OC(
- each R b6 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-.
- each R H is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, CN, C 1-6 alkoxy, C 1-6 haloalkoxy, amino, C 1-6 alkylamino, di-C 1-6 alkylamino, C 1-6 alkylsulfonyl, aminosulfonyl, C 1-6 alkylaminosulfonyl, di-C 1-6 alkylaminosulfonyl, and C 1-6 alkylsulfonylamino; wherein said C 1-6 alkyl is optionally substituted by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected halogens.
- each R e5 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- each R h5 and R i5 is independently selected from H, C 1-6 haloalkyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 alkyl-, C 3-7 cycloalkyl-C 1-6 alkyl-, (5-6 membered heteroaryl)-C 1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
- Cy 1 is not pyridin-4-yl optionally substituted with 1, 2, 3, or 4 independently selected R E substituents;
- R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R G substituents;
- each R b1 and R b2 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6
- each R f4 and R g4 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R h4 and R i4 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R e5 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
- each R b7 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-,
- R 1 is selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 1-6 haloalkyl;
- Cy 2 is C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R E substituents;
- each R h4 and R i4 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R f5 and R g5 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
- each R j6 and R k6 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- each R j7 and R k7 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- each R j2 and R k2 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy;
- each R f5 and R g5 is independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- each R e6 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
- C 3-6 cycloalkyl, phenyl, 5-10 membered heteroaryl, and 5-10 membered heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents selected from C 1-3 alkyl, C 1-3 alkyl-OH, halo, CN, C 1-3 alkoxy, and C(O)NH 2
- Cy 2 is selected from C 3-6 cycloalkyl, phenyl, 5-10 membered heteroaryl, and 5-10 membered heterocycloalkyl;
- the optionally substituted Cy 2 is selected from 2,6-dimethylpyridin-4-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 1-carbamoyl-1,2,3,6-tetrahydropyridin-4-yl, 1-carbamoylpiperidin-4-yl, 2-methoxypyridin-4-yl, 2-methoxy-6-methylpyridin-4-yl, 2,6-dimethylpyridin-4-yl-1-oxide, 1-ethyl-6-oxo-1,6-dihydropyridin-3-yl, 3-methylpyridin-4-yl, 3-fluoropyridin-4-yl, 3-chloropyridin-4-yl, 3-methoxypyridin-4-yl, 3-cyanopyridin-4-yl, 4-carbamoylphenyl, pyrazolo[1,5-a]pyridin-3-yl, pyrazolo[1,5-didin
- the optionally substituted Cy 2 is selected from 2,6-dimethylpyridin-4-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 1-carbamoyl-1,2,3,6-tetrahydropyridin-4-yl, 1-carbamoylpiperidin-4-yl, 2-methoxypyridin-4-yl, 2,6-dimethylpyridin-4-yl-1-oxide, 1-ethyl-6-oxo-1,6-dihydropyridin-3-yl, 3-methylpyridin-4-yl, 3-fluoropyridin-4-yl, 3-chloropyridin-4-yl, 3-methoxypyridin-4-yl, 3-cyanopyridin-4-yl, 4-carbamoylphenyl, pyrazolo[1,5-a]pyridin-3-yl, 5-methyl-1H-pyrazol-4-yl, 1-ethyl-1H-pyra
- R 1 is selected from H, C 1-6 alkyl, and 5-8 membered heteroaryl, wherein the 5-8 membered heteroaryl is optionally substituted by 1 or 2 independently selected R B substituents.
- R 1 is H or C 1-6 alkyl.
- R 1 is H, ethyl, or nicotinonitrile.
- R 1 is pyridyl which is optionally substituted by cyano.
- R 1 is 3-cyanopyridyl.
- R 2 is selected from C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected R C substituents.
- R 2 is selected from H, C 1-6 alkyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, OR a2 , NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , and C(O)OR a2 , wherein the C 1-6 alkyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C
- R 2 is selected from H, C 1-6 alkyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, OR a2 , NR c2 R d2 , C(O)R b2 , C(O)NR c2 R d2 , and C(O)OR a2 , wherein the C 1-6 alkyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-14 aryl-C 1-6 alkyl-, C 3-14 cycloalkyl-C
- R 2 is selected from H, C 6-14 aryl, 5-14 membered heteroaryl, C(O)R b2 , C(O)NR c2 R d2 , and C(O)OR a2 , wherein the C 6-14 aryl and 5-14 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R C substituents.
- the optionally substituted R 2 is selected from pyridinylmethyl, hydroxy(phenyl)methyl, hydroxyethylamino(phenyl)ethyl, cyclohexylmethyl, fluorobenzyl, hydroxy(fluorophenyl)methyl, (methylpyridinyl)methyl, (fluoropyridinyl)methyl, (trifluoromethylpyridinyl)methyl, ((hydroxymethyl)pyridinyl)methyl, (methoxypyridinyl)methyl, (methylpyrazolyl)benzyl, (methylpyrazolyl)methyl, benzoisoxazolylmethyl, (methylindazolyl)methyl, (hydroxyazetidinyl)methyl, benzoyl, phenylcyclopropyl, (cyano(phenyl)methyl)amino, tetrahydrofuranyl, phenyl(pyridinyloxy)methyl, fluoro ((fluorohydroxypyrrol)methyl,
- R 2 is selected from pyridinylmethyl, hydroxy(phenyl)methyl, hydroxyethylamino(phenyl)ethyl, cyclohexylmethyl, fluorobenzyl, hydroxy(fluorophenyl)methyl, (methylpyridinyl)methyl, (fluoropyridinyl)methyl, (methoxypyridinyl)methyl, (methylpyrazolyl)benzyl, benzoisoxazolylmethyl, (methylindazolyl)methyl, (hydroxyazetidinyl)methyl, benzoyl, phenylcyclopropyl, (cyano(phenyl)methyl)amino, tetrahydrofuranyl, and phenyl(pyridinyloxy)methyl.
- R 2 is selected from pyridin-2-ylmethyl, hydroxy(phenyl)methyl, (2-hydroxyethylamino)(phenyl)methyl, cyclohexylmethyl, 2-fluorobenzyl, (2-fluorophenyl)(hydroxy)methyl, (6-methylpyridin-2-yl)methyl, (3-fluoropyridin-2-yl)methyl, (3-methoxypyridin-2-yl)methyl, 2-(1-methyl-1H-pyrazol-4-yl)benzyl, benzo[d]isoxazol-3-ylmethyl, (1-methyl-1H-indazol-3-yl)methyl, (3-hydroxyazetidin-1-yl)methyl, benzoyl, 1-phenylcyclopropyl, (cyano(phenyl)methyl)amino, tetrahydrofuran-3-yl, phenyl(pyridin-2-yloxy)methyl, 2-fluoro-6-((((())
- R c2 and R d2 are each independently selected from H, C 1-6 alkyl, 5-14 membered heteroaryl, and C 6-14 aryl-C 1-6 alkyl-, wherein the C 1-6 alkyl, 5-14 membered heteroaryl, and C 6-14 aryl-C 1-6 alkyl- are each optionally substituted with 1, 2, or 3 independently selected R G substituents.
- each R c4 and R d4 are independently selected from H and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2, or 3 independently selected R H substituents.
- each R a5 , and R c5 is selected from H and C 1-6 alkyl.
- R 3 is selected from H, D, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 6-14 aryl, 5-14 membered heteroaryl, CN, and OR a3 , wherein the C 1-6 alkyl, C 6-14 aryl, and 5-14 membered heteroaryl of R 3 are each optionally substituted with 1, 2, 3, or 4 independently selected R D substituents;
- Cy 1 is phenyl optionally substituted with 1, 2, 3, or 4 independently selected R M substituents, or C 10-14 aryl or 5-14 membered heteroaryl, wherein the C 10-14 aryl and 5-14 membered heteroaryl of Cy 1 is optionally substituted with 1, 2, 3, or 4 independently selected R E substituents;
- each R a2 , R c2 , R d2 , and R a3 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R a2 , R c2 , R d2 , and R a3 are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents;
- each R J is independently selected from D, halo, oxo, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CN, NO 2 , OR a7 , SR a7 , NHOR a7 , C(O)R b7 , C(O)NR c7 R d7 , C(O)OR a7 , OC(O)R b7 , OC(O)NR c7 R d7 , NR c7 R d7 , NR c7 C(O)R b7 , NR c7 C(O)OR a7 , NR c7 C(O)NR c7 R d7 , C( ⁇ NR e7 )R b7 , C
- each R a7 , R c7 , and R d7 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R a7 , R c7 , and R d7 are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
- each R b7 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
- X is CR 3 ;
- each R e4 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, and C 1-6 haloalkoxy;
- each R b2 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents;
- Cy 2 is C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl or 4-14 membered heterocycloalkyl, wherein the C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl and 4-14 membered heterocycloalkyl of Cy 2 are each optionally substituted with 1, 2, 3, or 4 independently selected R E substituents;
- each R B , R C , R E , R F , and R G is independently selected from D, halo, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CN, NO 2 , OR a4 , SR a4 , NHOR a4 , C(O)R b4 , C(O)NR c4 R d4 , C(O)OR a4 , OC(O)R b4 , OC(O)NR c4 R d4 , NR c4 R d4 , NR c4 C(O)R b4 , NR c4 C(O)OR a4 , NR c4 C(O)NR c4 R d4 , C( ⁇ NR e4 )
- X is N
- each R E is independently selected from D, halo, oxo, C 1-6 alkyl, C 2-6 alkenyl, CN, NO 2 , and OR a4 , wherein the C 1-6 alkyl and C 2-6 alkenyl of R E are each optionally substituted with 1, 2, or 3 independently selected R H substituents;
- each R a4 is independently selected from H, C 1-6 alkyl and C 1-6 alkoxy;
- each R H is independently selected from D, halo, oxo, C 1-6 alkyl, CN, NO 2 and OH.
- each R E is independently selected from D, halo, oxo, C 1-6 alkyl, C 2-6 alkenyl, CN, NO 2 , and OR a4 , wherein the C 1-6 alkyl and C 2-6 alkenyl of R E are each optionally substituted with 1, 2, or 3 independently selected R H substituents;
- Cy 1 is cyanophenyl
- n-membered where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
- piperidinyl is an example of a 6-membered heterocycloalkyl ring
- pyrazolyl is an example of a 5-membered heteroaryl ring
- pyridyl is an example of a 6-membered heteroaryl ring
- 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
- C n-m alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons.
- Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like.
- the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
- aryl refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings).
- C n-m aryl refers to an aryl group having from n to m ring carbon atoms.
- Aryl groups include, e.g., phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like.
- aryl groups have from 5 to 14 carbon atoms.
- the aryl group has from 5 to 10 carbon atoms.
- the aryl group is phenyl or naphthyl.
- the aryl group is phenyl.
- halo refers to F, Cl, Br, or I. In some embodiments, a halo is F, Cl, or Br. In some embodiments, a halo is F or Cl. In some embodiments, a halo is F. In some embodiments, a halo is Cl.
- C n-m haloalkyl refers to an alkyl group having from one halogen atom to 2s+1 halogen atoms which may be the same or different, where “s” is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms.
- the haloalkyl group is fluorinated only.
- the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
- Example haloalkyl groups include CF 3 , C 2 F 5 , CHF 2 , CCl 3 , CHCl 2 , C 2 Cl 5 and the like.
- the cycloalkyl is a C 3-14 monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 4-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 4-10 spirocycle or bridged cycloalkyl (e.g., a bridged bicycloalkyl group).
- heteroaryl refers to a monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) aromatic heterocycle having at least one heteroatom ring member selected from N, O, S, and B.
- the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S and B.
- any ring-forming N in a heteroaryl moiety can be an N-oxide.
- the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S, and B.
- the heteroaryl is a 5-6 monocyclic heteroaryl having 1, 2, or 3 heteroatom ring members independently selected from N, O, S, and B.
- the heteroaryl is a five-membered or six-membered heteroaryl ring.
- a five-membered heteroaryl ring is a heteroaryl with a ring having five ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, S, and B.
- the heteroaryl group contains 3 to 14, 4 to 14, 3 to 7, or 5 to 6 ring-forming atoms.
- Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, isoxazole, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[1, 2-b]thiazole, purine, triazine, thieno[3,2-b]pyridine, imidazo[1,2-a]pyridine, 1,5-naphthyridine, 1H-pyrazolo[4,3-b]pyridine, and the like.
- Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2, 3, or 4 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-14-, 4-14-, 3-10-, 4-10-, 5-10-, 4-7-, 5-7-, 5-6-, 5- or 6-membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-14 membered bridged biheterocycloalkyl ring having one or more ring-forming carbon atoms replaced by a heteroatom independently selected from N, O, S, and B).
- spirocycles and bridged rings e.g., a 5-14 membered bridged biheterocycloalkyl ring having one or more ring-forming carbon atoms replaced by a heteroatom independently selected from N, O, S, and B).
- alkyl linking groups or “alkylene groups” include methylene, ethan-1,1-diyl, ethan-1,2-diyl, propan-1,3-dilyl, propan-1,2-diyl, propan-1,1-diyl and the like.
- resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of ⁇ -methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.
- the compounds provided herein, or salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, for example, a composition enriched in the compounds provided herein.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- the present application also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- ACN acetonitrile
- Compound of formula 10 can be prepared via the synthetic route as outlined in Scheme 1.
- the commercially available starting material 1 can undergo a halogenation reaction, such as electrophilic aromatic substitution (S E Ar), with an appropriate reagent, such as N-bromosuccinimide (NBS), to afford compound 2 (Hal is a halide, such as F, Cl, Br, or I).
- Condensation of compound 2 with a carbonyl adduct of formula 3 at elevated temperature can generate the bicyclic compound 4.
- Selective chloride displacement of compound 4 via either nucleophilic substitution, or a coupling reaction, with compound 5 can deliver compound 6.
- compound of formula 10 can be prepared via the synthetic route as outlined in Scheme 2.
- the commercially available starting material 11 can undergo a coupling reaction with an adduct of formula 9, in which M is a boronic acid, a boronic ester or an appropriately substituted metal [e.g., M is B(OR) 2 , Sn(Alkyl) 3 , Zn-Hal, etc.], under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst), to give a derivative of formula 12.
- M is a boronic acid, a boronic ester or an appropriately substituted metal
- Compound 21 can then be subjected to a halogenation reaction, such as electrophilic aromatic substitution (S E Ar), with an appropriate reagent, such as N-bromosuccinimide (NBS), to afford compound 22 (Hal is a halide, such as F, Cl, Br, or I).
- a halogenation reaction such as electrophilic aromatic substitution (S E Ar)
- NBS N-bromosuccinimide
- Condensation of compound 22 with a carbonyl adduct of formula 3a at elevated temperature can generate the bicyclic compound of formula 23.
- Oxidation of compound 23 with an appropriate oxidant, such as mCPBA, followed by nucleophilic substitution with a protected amine adduct 24 can deliver compound 25.
- Compound 10c can also be prepared using the synthetic route as outlined in Scheme 6.
- Compound 22 (prepared as described in Scheme 5) can first undergo a coupling reaction with an adduct of formula 7, in which M is a boronic acid, a boronic ester or an appropriately substituted metal [e.g., M is B(OR) 2 , Sn(Alkyl) 3 , Zn-Hal, etc.], under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst), to give a derivative of formula 27.
- Condensation of compound 27 with a carbonyl adduct of formula 3a at elevated temperature can generate the bicyclic compound of formula 28.
- Compound 28 can then react with amine 19 and amine 5, in either
- Compounds 10d can be prepared using the synthetic route as outlined in Scheme 7. Condensation of commercially available starting material 29 with a carbonyl adduct of formula 3a at elevated temperature can generate the bicyclic compound of formula 30. Compound 30 can then undergo a coupling reaction with an adduct of formula 9, in which M is a boronic acid, a boronic ester or an appropriately substituted metal [e.g., M is B(OR) 2 , Sn(Alkyl) 3 , Zn-Hal, etc.], under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst), to give a derivative of formula 31.
- M is a boronic acid, a boronic ester or an appropriately substituted metal
- Compound 31 can then be subjected to a halogenation reaction, such as electrophilic aromatic substitution (S E Ar), with an appropriate reagent, such as N-bromosuccinimide (NBS), to afford compound 32 (Hal is a halide, such as F, Cl, Br, or I).
- a halogenation reaction such as electrophilic aromatic substitution (S E Ar)
- NSS N-bromosuccinimide
- Ester hydrolysis of compound 32 in the presence of an appropriate reagent, such as lithium hydroxide (LiOH) can generate the corresponding carboxylic acid, which can then be coupled with an amine adduct of formula 19, using an appropriate coupling reagent (such as HATU, BOP, or PyBOP), to afford compound 33.
- an appropriate coupling reagent such as HATU, BOP, or PyBOP
- Cy 2 can then be achieved by the coupling of compound 33 with an adduct of formula 7, using similar conditions as described for the preparation of compound 31 from compound 30, to
- M is a boronic acid, boronic ester or an appropriately substituted metal [e.g., M is B(OR) 2 , Sn(Alkyl) 3 , or Zn-Hal], under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst).
- M is a boronic acid, boronic ester or an appropriately substituted metal
- M is B(OR) 2 , Sn(Alkyl) 3 , or Zn-Hal
- Suzuki cross-coupling conditions e.g., in the presence of a palladium catalyst and a suitable base
- Stille cross-coupling conditions e.g., in the presence of a palladium catalyst
- Negishi cross-coupling conditions e.g
- the compounds or salts described herein can be selective.
- selective it is meant that the compound binds to or inhibits an adenosine receptor with greater affinity or potency, respectively, compared to at least one other receptor, kinase, etc.
- the compounds of the present disclosure can also be dual antagonists (i.e., inhibitors) of adenosine receptors, e.g., A2A and A2B adenosine receptors.
- the disease or disorder is lung cancer (e.g., non-small cell lung cancer), melanoma, pancreatic cancer, breast cancer, head and neck squamous cell carcinoma, prostate cancer, liver cancer, color cancer, endometrial cancer, bladder cancer, skin cancer, cancer of the uterus, renal cancer, gastric cancer, or sarcoma.
- lung cancer e.g., non-small cell lung cancer
- melanoma pancreatic cancer
- breast cancer head and neck squamous cell carcinoma
- prostate cancer liver cancer
- color cancer endometrial cancer
- bladder cancer skin cancer
- cancer of the uterus cancer of the uterus
- renal cancer gastric cancer
- sarcoma sarcoma
- immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD20, CD28, CD40, CD122, CD96, CD73, CD47, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, HPK1, CD137 (also known as 4-1BB), ICOS, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, TIGIT, PD-1, PD-L1 and PD-L2.
- the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137.
- the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD1 antibody is SHR-1210.
- Other anti-cancer agent(s) include antibody therapeutics such as 4-1BB (e.g. urelumab, utomilumab.
- the inhibitor of an immune checkpoint molecule is an agonist of OX40, e.g., OX40 agonist antibody or OX40L fusion protein.
- OX40 e.g., OX40 agonist antibody or OX40L fusion protein.
- the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS-986178.
- the OX40L fusion protein is MEDI6383.
- the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody.
- the anti-CD20 antibody is obinutuzumab or rituximab.
- the compounds of the disclosure can be used in combination with one or more metabolic enzyme inhibitors.
- the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO, or arginase.
- IDO1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
- the additional compounds, inhibitors, agents, etc. can be combined with the present compound in a single or continuous dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
- the compounds of the present disclosure can be used in combination with one or more other enzyme/protein/receptor inhibitors or one or more therapies for the treatment of diseases, such as cancer.
- diseases and indications treatable with combination therapies include those as described herein.
- Example antibodies for use in combination therapy include but are not limited to Trastuzumab (e.g. anti-HER2), Ranibizumab (e.g. anti-VEGF-A), Bevacizumab (trade name Avastin, e.g. anti-VEGF, Panitumumab (e.g. anti-EGFR), Cetuximab (e.g. anti-EGFR), Rituxan (anti-CD20) and antibodies directed to c-MET.
- Trastuzumab e.g. anti-HER2
- Ranibizumab e.g. anti-VEGF-A
- Bevacizumab trade name Avastin, e.g. anti-VEGF, Panitumumab (e.g. anti-EGFR), Cetuximab (e.g. anti-EGFR), Rituxan (anti-CD20) and antibodies directed to c-MET.
- cytostatic agent cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, IRESSATM, (gefitinib), TARCEVATM, (erlotinib), antibodies to EGFR, GLEEVECTM, intron, ara-C, adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman,
- Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVACTM), nilotinib, dasatinib, bosutinib, and ponatinib, and pharmaceutically acceptable salts.
- Other example suitable Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, and U.S. Ser. No. 60/578,491.
- Example suitable Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib, maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215, and their pharmaceutically acceptable salts.
- Other example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.
- the agents can be combined with the present compound in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
- combinations of the compounds of the disclosure with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant.
- the compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
- the compounds of the disclosure can be administered in the form of pharmaceutical compositions.
- These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral, or parenteral.
- topical including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery
- pulmonary e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal
- oral or parenteral.
- compositions of the disclosure contain from about 50 to about 500 mg of the active ingredient.
- all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms.
- a labeled compound of the disclosure can be used in a screening assay to identify/evaluate compounds.
- a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind an adenosine receptor by monitoring its concentration variation when contacting with the adenosine receptor, through tracking of the labeling.
- a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to an adenosine receptor (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the adenosine receptor directly correlates to its binding affinity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/285,787 US20190292188A1 (en) | 2018-02-27 | 2019-02-26 | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
US17/077,713 US11673894B2 (en) | 2018-02-27 | 2020-10-22 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US18/300,349 US20230357255A1 (en) | 2018-02-27 | 2023-04-13 | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862635926P | 2018-02-27 | 2018-02-27 | |
US201862718216P | 2018-08-13 | 2018-08-13 | |
US201862721312P | 2018-08-22 | 2018-08-22 | |
US201962793015P | 2019-01-16 | 2019-01-16 | |
US16/285,787 US20190292188A1 (en) | 2018-02-27 | 2019-02-26 | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/077,713 Continuation US11673894B2 (en) | 2018-02-27 | 2020-10-22 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190292188A1 true US20190292188A1 (en) | 2019-09-26 |
Family
ID=65911247
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/285,787 Abandoned US20190292188A1 (en) | 2018-02-27 | 2019-02-26 | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
US17/077,713 Active US11673894B2 (en) | 2018-02-27 | 2020-10-22 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US18/300,349 Pending US20230357255A1 (en) | 2018-02-27 | 2023-04-13 | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/077,713 Active US11673894B2 (en) | 2018-02-27 | 2020-10-22 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US18/300,349 Pending US20230357255A1 (en) | 2018-02-27 | 2023-04-13 | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
Country Status (19)
Country | Link |
---|---|
US (3) | US20190292188A1 (zh) |
EP (1) | EP3759112A1 (zh) |
JP (2) | JP7474709B2 (zh) |
KR (1) | KR20200139153A (zh) |
CN (2) | CN117903140A (zh) |
AU (2) | AU2019227607C1 (zh) |
BR (2) | BR122023024273A2 (zh) |
CA (1) | CA3092470A1 (zh) |
CL (2) | CL2020002198A1 (zh) |
CO (1) | CO2020011908A2 (zh) |
CR (2) | CR20200441A (zh) |
EC (1) | ECSP20060827A (zh) |
IL (2) | IL303087A (zh) |
MA (1) | MA52422A (zh) |
MX (2) | MX2020008949A (zh) |
PE (1) | PE20211001A1 (zh) |
PH (1) | PH12020551332A1 (zh) |
TW (2) | TW202000666A (zh) |
WO (1) | WO2019168847A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10793561B2 (en) | 2017-07-18 | 2020-10-06 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
WO2021138498A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
US11161850B2 (en) * | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US11306071B2 (en) | 2019-01-18 | 2022-04-19 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
WO2022147092A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
US11390624B2 (en) | 2019-01-29 | 2022-07-19 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11673894B2 (en) | 2018-02-27 | 2023-06-13 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
WO2023246846A1 (zh) * | 2022-06-23 | 2023-12-28 | 成都恒昊创新科技有限公司 | 一种非螯合性非还原性铁死亡抑制剂及其制备方法和用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3575301A4 (en) * | 2017-03-16 | 2020-08-05 | Jiangsu Hengrui Medicine Co., Ltd. | HETEROARYL [4,3-C] PYRIMIDINE-5-AMINE DERIVATIVE, PROCESS FOR PREPARATION AND MEDICAL USES |
PT3611174T (pt) * | 2017-04-07 | 2022-07-07 | Medshine Discovery Inc | Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inibidor do recetor a2a |
AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
EP3883575A4 (en) * | 2018-11-20 | 2022-06-15 | Merck Sharp & Dohme Corp. | SUBSTITUTE AMINO-TRIAZOLOPYRIMIDINE AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
BR112021009880A2 (pt) * | 2018-11-30 | 2021-08-17 | Tuojie Biotech (Shanghai) Co., Ltd. | pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos |
CA3150766A1 (en) * | 2019-08-26 | 2021-03-04 | Incyte Corporation | Triazolopyrimidines as a2a / a2b inhibitors |
AU2020417813A1 (en) | 2020-01-03 | 2022-08-25 | Incyte Corporation | Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors |
WO2021156439A1 (en) * | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
CN111362939B (zh) * | 2020-04-26 | 2021-08-03 | 山东梅奥华卫科技有限公司 | 一种帕布昔利布母核结构化合物的制备方法 |
WO2023091604A1 (en) * | 2021-11-19 | 2023-05-25 | Crossignal Therapeutics, Inc. | Adenosine receptor antagonists |
KR102621694B1 (ko) * | 2022-09-15 | 2024-01-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0976753A1 (en) * | 1997-03-24 | 2000-02-02 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
US20070010522A1 (en) * | 2003-04-09 | 2007-01-11 | Chi Vu | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
US20180009816A1 (en) * | 2016-06-24 | 2018-01-11 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS |
WO2018184590A1 (zh) * | 2017-04-07 | 2018-10-11 | 南京明德新药研发股份有限公司 | 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 |
Family Cites Families (257)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
DE19629378A1 (de) | 1996-07-20 | 1998-01-29 | Boehringer Ingelheim Kg | Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
AU756144B2 (en) | 1998-09-22 | 2003-01-02 | Kyowa Hakko Kogyo Co. Ltd. | (1,2,4)triazolo(1,5-c)pyrimidine derivatives |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
DE60024436T2 (de) | 1999-05-07 | 2006-08-17 | Genentech, Inc., South San Francisco | Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden |
JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Pd−1、b7−4の受容体、およびその使用 |
ATE353365T1 (de) | 1999-08-23 | 2007-02-15 | Dana Farber Cancer Inst Inc | Neue b7-4 moleküle und deren verwendungen |
US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
CA2392477A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
CA2405632A1 (en) | 2000-04-25 | 2001-11-01 | Idec Pharmaceutical Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
KR100520907B1 (ko) | 2000-05-26 | 2005-10-11 | 쉐링 코포레이션 | 아데노신 A2a수용체 길항제 |
PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
WO2002014282A1 (fr) | 2000-08-11 | 2002-02-21 | Eisai Co., Ltd. | Composes 2-aminopyridine et leur utilisation comme medicaments |
ATE418565T1 (de) | 2001-01-17 | 2009-01-15 | Intreat Pty Ltd | Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden |
AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
JP2004536807A (ja) | 2001-05-30 | 2004-12-09 | アルテオン インコーポレイテッド | 緑内障vの治療方法 |
WO2002096363A2 (en) | 2001-05-30 | 2002-12-05 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
CA2466243A1 (en) | 2001-09-19 | 2003-03-27 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
WO2003031587A2 (en) | 2001-10-09 | 2003-04-17 | The Regents Of The University Of California | Use of stat-6 inhibitors as therapeutic agents |
KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
CN101001857B (zh) | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
AU2003211993A1 (en) | 2002-02-15 | 2003-09-04 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
JPWO2004029056A1 (ja) | 2002-09-24 | 2006-01-26 | 協和醗酵工業株式会社 | [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体 |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
TW201018661A (en) | 2003-03-14 | 2010-05-16 | Ono Pharmaceutical Co | Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
PL1613350T3 (pl) | 2003-04-09 | 2009-08-31 | Genentech Inc | Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα |
EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
EP1633756B1 (en) | 2003-04-09 | 2008-12-24 | Biogen Idec MA Inc. | A2a adenosine receptor antagonists |
AU2004244906A1 (en) | 2003-06-10 | 2004-12-16 | Kyowa Hakko Kirin Co., Ltd. | A method of treating an anxiety disorder |
CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
RU2376292C2 (ru) | 2003-08-14 | 2009-12-20 | Ф.Хоффманн-Ля Рош Аг | Гамк-ергические модуляторы |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US8362017B2 (en) | 2003-08-29 | 2013-01-29 | Exelixis, Inc. | C-kit modulators and methods of use |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
GB0403819D0 (en) | 2004-02-20 | 2004-03-24 | Merck Sharp & Dohme | New compounds |
JP2007529496A (ja) | 2004-03-19 | 2007-10-25 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体 |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2008503562A (ja) | 2004-06-23 | 2008-02-07 | イデニクス(ケイマン)リミテツド | フラビウイルス科による感染症を治療するための5−アザ−7−デアザプリン誘導体 |
US20050288502A1 (en) | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
JP4938673B2 (ja) | 2004-10-15 | 2012-05-23 | ベリサイン・インコーポレイテッド | ワンタイムパスワード |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20060211739A1 (en) | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
RU2007142523A (ru) | 2005-05-18 | 2009-06-27 | БИОГЕН ИДЕК Инк. (US) | Способы лечения фиброзных состояний |
WO2006129626A1 (ja) | 2005-05-30 | 2006-12-07 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法 |
US7851478B2 (en) | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
JP4986451B2 (ja) | 2005-06-30 | 2012-07-25 | 信一郎 礒部 | マーキング剤 |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
CA2620223A1 (en) | 2005-09-02 | 2007-03-08 | Abbott Laboratories | Novel imidazo based heterocycles |
AU2006315718B2 (en) | 2005-11-10 | 2012-10-04 | Merck Sharp & Dohme Corp. | Imidazopyrazines as protein kinase inhibitors |
ES2436877T3 (es) | 2005-11-17 | 2014-01-07 | OSI Pharmaceuticals, LLC | Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados |
US8349850B2 (en) | 2006-03-28 | 2013-01-08 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
WO2007138072A2 (en) | 2006-05-31 | 2007-12-06 | Galapagos N.V. | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases |
KR20090025261A (ko) | 2006-06-23 | 2009-03-10 | 인사이트 코포레이션 | Hm74a 아고니스트로서의 퓨리논 유도체 |
EP2037905B1 (en) | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
EP2078732B1 (en) | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
WO2008011560A2 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
DE102006041292A1 (de) | 2006-09-01 | 2008-03-06 | Henkel Kgaa | Wasserstoffperoxid-Aktivierung mit N-Heterocyclen |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
WO2008070599A1 (en) | 2006-12-05 | 2008-06-12 | Chung-Ming Sun | Indazole compounds |
DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
KR20090130109A (ko) | 2007-04-10 | 2009-12-17 | 하. 룬트벡 아크티에 셀스카브 | P2x7 길항제로서의 헤테로아릴 아미드 유사체 |
US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
WO2008138843A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases |
WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
HUP0700395A2 (en) | 2007-06-07 | 2009-03-02 | Sanofi Aventis | Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
AU2008277628B2 (en) | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
EP2187883A2 (en) | 2007-08-10 | 2010-05-26 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CN101801379A (zh) | 2007-10-18 | 2010-08-11 | 诺瓦提斯公司 | 治疗癌症和骨疾病的csf-1r抑制剂 |
US20090118301A1 (en) | 2007-11-02 | 2009-05-07 | Arbor Vita Corporation | Compositions and Methods for Treating Cancer |
US20100292232A1 (en) | 2007-11-09 | 2010-11-18 | Daniel Elleder | Non-nucleoside reverse transcriptase inhibitors |
PE20091074A1 (es) | 2007-12-13 | 2009-07-26 | Bayer Healthcare Ag | Triazolotriazinas y triazolopirazinas y su uso |
KR20100095020A (ko) | 2007-12-19 | 2010-08-27 | 암젠 인크 | 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물 |
US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
KR101632450B1 (ko) | 2008-03-21 | 2016-06-21 | 엔쏜 인코포레이티드 | 다작용기성 화합물을 이용한 적층체에 대한 금속의 접착 촉진 |
US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
EP2444403A1 (en) | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
TWI473614B (zh) | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
US9254283B2 (en) | 2008-07-23 | 2016-02-09 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for migraine |
US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
WO2010032874A1 (ja) | 2008-09-19 | 2010-03-25 | 住友化学株式会社 | 農業用組成物 |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
MX2011006332A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
WO2010104306A2 (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
CA2771532C (en) | 2009-08-17 | 2021-03-23 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
EP2347769A1 (en) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
KR101732212B1 (ko) | 2010-03-18 | 2017-05-02 | 재단법인 한국파스퇴르연구소 | 항감염성 화합물 |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
GB201007187D0 (en) | 2010-04-29 | 2010-06-09 | Iti Scotland Ltd | Ubiquitination modulators |
WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
US20120083498A1 (en) | 2010-06-17 | 2012-04-05 | Fatah Kashanchi | Modulators of Viral Transcription, and Methods and Compositions Therewith |
JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体 |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
ES2614128T3 (es) | 2010-08-27 | 2017-05-29 | Merck Patent Gmbh | Derivados de triazolopirazina |
DK2632467T3 (en) | 2010-10-25 | 2016-08-15 | G1 Therapeutics Inc | CDK inhibitors |
CN104906103B (zh) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
EP2663565B1 (en) | 2011-01-11 | 2017-03-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
EP2604265A1 (en) | 2011-12-17 | 2013-06-19 | Royal College of Surgeons in Ireland (RCSI) | P2x7 antagonists as frontline or adjunctive treatment against status epilepticus |
WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
WO2013178572A1 (en) | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Triazolo compounds as pde10 inhibitors |
WO2013191112A1 (ja) | 2012-06-22 | 2013-12-27 | 住友化学株式会社 | 縮合複素環化合物 |
JP2015528013A (ja) | 2012-07-27 | 2015-09-24 | ビアル−ポルテラ エ コンパニア,ソシエダッド アノニマ | 置換ウレア化合物の合成方法 |
EP2919770A4 (en) | 2012-11-14 | 2017-03-08 | The Board of Regents of The University of Texas System | Inhibition of hif-2 heterodimerization with hif1 (arnt) |
WO2014126580A1 (en) | 2013-02-15 | 2014-08-21 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
EP2968304B1 (en) | 2013-03-14 | 2018-10-10 | The Trustees of Columbia University in the City of New York | 4-phenylpiperidines, their preparation and use |
US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
WO2014153424A1 (en) | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
EP3204007B1 (en) | 2014-10-06 | 2023-12-20 | Apm Therapeutics 1, Inc. | Triazolopyridine compounds and methods for the treatment of cystic fibrosis |
BR112017006464A2 (pt) | 2014-10-10 | 2018-01-30 | Innate Pharma | bloqueio de cd73 |
US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
DK3218406T3 (da) | 2014-11-10 | 2021-06-21 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
US20160129108A1 (en) | 2014-11-11 | 2016-05-12 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and uses thereof |
US10100129B2 (en) | 2014-11-21 | 2018-10-16 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
PL3257853T3 (pl) | 2015-02-12 | 2022-03-21 | Nissan Chemical Corporation | Skondensowany związek heterocykliczny i środek zwalczający szkodliwe organizmy |
EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
MX2018001227A (es) | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
CA3007646A1 (en) | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
US20170174671A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
EP3393475A4 (en) | 2015-12-24 | 2019-08-14 | Corvus Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
EP3419978B1 (en) | 2016-02-24 | 2020-04-15 | Pfizer Inc | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
IL261606B (en) | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
EP3452476B1 (en) | 2016-05-06 | 2021-12-15 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PT3472167T (pt) | 2016-06-20 | 2022-11-11 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
WO2018004478A1 (en) | 2016-06-29 | 2018-01-04 | Hayat Kimya San. A. Ş. | An improved method of soft nonwoven fabric production |
EP3481869A4 (en) | 2016-07-11 | 2020-02-26 | Corvus Pharmaceuticals, Inc. | ANTI-CD73 ANTIBODY |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
LT3507291T (lt) | 2016-09-02 | 2021-09-10 | Cyclerion Therapeutics, Inc. | Kondensuoti bicikliniai sgc stimuliatoriai |
WO2018110555A1 (ja) | 2016-12-13 | 2018-06-21 | アステラス製薬株式会社 | 抗ヒトcd73抗体 |
MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
HUE060233T2 (hu) | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek |
MA47099A (fr) | 2016-12-22 | 2021-05-12 | Incyte Corp | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs |
US20180177784A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ,インコーポレイテッド | アロステリックshp2阻害剤としての二環式化合物 |
US10584169B2 (en) | 2017-01-24 | 2020-03-10 | I-Mab Biopharma Us Limited | Anti-CD73 antibodies and uses thereof |
EP3575301A4 (en) * | 2017-03-16 | 2020-08-05 | Jiangsu Hengrui Medicine Co., Ltd. | HETEROARYL [4,3-C] PYRIMIDINE-5-AMINE DERIVATIVE, PROCESS FOR PREPARATION AND MEDICAL USES |
EP3606962A4 (en) | 2017-04-04 | 2020-12-23 | Corvus Pharmaceuticals, Inc. | TREATMENT METHODS FOR HIGH CD73 TUMORS |
CN110753703B (zh) | 2017-05-23 | 2024-04-09 | 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) | 新的cd73抗体、其制备和用途 |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EA202090104A1 (ru) | 2017-06-22 | 2020-04-09 | Новартис Аг | Молекулы антител к cd73 и пути их применения |
WO2019002606A1 (en) | 2017-06-30 | 2019-01-03 | Selvita S.A. | ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS |
CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
SG11202003641RA (en) | 2017-10-24 | 2020-05-28 | Bayer Ag | Substituted imidazopyridine amides and use thereof |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
CA3089561A1 (en) | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
AU2019215049A1 (en) | 2018-01-31 | 2020-09-17 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
US11420984B2 (en) | 2018-02-17 | 2022-08-23 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
CR20200441A (es) | 2018-02-27 | 2021-03-15 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
WO2019170131A1 (zh) | 2018-03-07 | 2019-09-12 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
BR112020016049A2 (pt) | 2018-03-09 | 2020-12-08 | Phanes Therapeutics, Inc. | Anticorpos anti-cd73 e seus usos |
WO2019173692A2 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
DK3774791T3 (da) | 2018-03-30 | 2023-01-23 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
KR20200142542A (ko) | 2018-04-12 | 2020-12-22 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법 |
PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
CN112955464A (zh) | 2018-06-20 | 2021-06-11 | 因赛特公司 | 抗pd-1抗体及其用途 |
TW202402759A (zh) | 2018-07-05 | 2024-01-16 | 美商英塞特公司 | 作為a2a/a2b抑制劑之稠合吡嗪衍生物 |
CR20210056A (es) | 2018-08-13 | 2021-03-02 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa |
MX2021001433A (es) | 2018-08-13 | 2021-04-12 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. |
GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
EP3840837B1 (en) | 2018-08-22 | 2024-03-20 | Astrazeneca AB | Arginase inhibitors and methods of use thereof |
AR116315A1 (es) | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
EP3856173A4 (en) | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS |
CN111295384B (zh) | 2018-10-10 | 2022-08-12 | 江苏豪森药业集团有限公司 | 双环类衍生物抑制剂、其制备方法和应用 |
UY38437A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
EP3889152A4 (en) | 2018-11-30 | 2022-09-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATORS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
CA3150766A1 (en) | 2019-08-26 | 2021-03-04 | Incyte Corporation | Triazolopyrimidines as a2a / a2b inhibitors |
KR20220075382A (ko) | 2019-09-30 | 2022-06-08 | 인사이트 코포레이션 | 면역조절제로서의 피리도[3,2-d]피리미딘 화합물 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
AU2020417813A1 (en) | 2020-01-03 | 2022-08-25 | Incyte Corporation | Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors |
CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
CA3207066A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
-
2019
- 2019-02-26 CR CR20200441A patent/CR20200441A/es unknown
- 2019-02-26 CN CN202311603774.9A patent/CN117903140A/zh active Pending
- 2019-02-26 BR BR122023024273-4A patent/BR122023024273A2/pt unknown
- 2019-02-26 IL IL303087A patent/IL303087A/en unknown
- 2019-02-26 BR BR112020017421-1A patent/BR112020017421A2/pt unknown
- 2019-02-26 CN CN201980027624.3A patent/CN112384515A/zh active Pending
- 2019-02-26 CA CA3092470A patent/CA3092470A1/en active Pending
- 2019-02-26 EP EP19713602.1A patent/EP3759112A1/en active Pending
- 2019-02-26 AU AU2019227607A patent/AU2019227607C1/en active Active
- 2019-02-26 TW TW108106559A patent/TW202000666A/zh unknown
- 2019-02-26 MA MA052422A patent/MA52422A/fr unknown
- 2019-02-26 JP JP2020567459A patent/JP7474709B2/ja active Active
- 2019-02-26 CR CR20230030A patent/CR20230030A/es unknown
- 2019-02-26 MX MX2020008949A patent/MX2020008949A/es unknown
- 2019-02-26 TW TW112133901A patent/TW202400599A/zh unknown
- 2019-02-26 US US16/285,787 patent/US20190292188A1/en not_active Abandoned
- 2019-02-26 PE PE2020001285A patent/PE20211001A1/es unknown
- 2019-02-26 KR KR1020207027865A patent/KR20200139153A/ko not_active Application Discontinuation
- 2019-02-26 WO PCT/US2019/019582 patent/WO2019168847A1/en unknown
-
2020
- 2020-08-23 IL IL276873A patent/IL276873A/en unknown
- 2020-08-26 CL CL2020002198A patent/CL2020002198A1/es unknown
- 2020-08-26 PH PH12020551332A patent/PH12020551332A1/en unknown
- 2020-08-27 MX MX2022014648A patent/MX2022014648A/es unknown
- 2020-09-25 CO CONC2020/0011908A patent/CO2020011908A2/es unknown
- 2020-09-25 EC ECSENADI202060827A patent/ECSP20060827A/es unknown
- 2020-10-22 US US17/077,713 patent/US11673894B2/en active Active
-
2022
- 2022-11-15 CL CL2022003185A patent/CL2022003185A1/es unknown
- 2022-12-05 AU AU2022283611A patent/AU2022283611A1/en active Pending
-
2023
- 2023-04-13 US US18/300,349 patent/US20230357255A1/en active Pending
- 2023-06-13 JP JP2023096889A patent/JP2023123569A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0976753A1 (en) * | 1997-03-24 | 2000-02-02 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
US20070010522A1 (en) * | 2003-04-09 | 2007-01-11 | Chi Vu | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
US20180009816A1 (en) * | 2016-06-24 | 2018-01-11 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS |
US20200102315A1 (en) * | 2016-06-24 | 2020-04-02 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS |
WO2018184590A1 (zh) * | 2017-04-07 | 2018-10-11 | 南京明德新药研发股份有限公司 | 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US10793561B2 (en) | 2017-07-18 | 2020-10-06 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US11673894B2 (en) | 2018-02-27 | 2023-06-13 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
US11873304B2 (en) | 2018-05-18 | 2024-01-16 | Incyte Corporation | Fused pyrimidine derivatives as A2A/A2B inhibitors |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
US20220135570A1 (en) * | 2018-07-05 | 2022-05-05 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
US11161850B2 (en) * | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
US11306071B2 (en) | 2019-01-18 | 2022-04-19 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US11390624B2 (en) | 2019-01-29 | 2022-07-19 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
US11884665B2 (en) | 2019-01-29 | 2024-01-30 | Incyte Corporation | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors |
WO2021138498A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
WO2022147092A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
WO2023246846A1 (zh) * | 2022-06-23 | 2023-12-28 | 成都恒昊创新科技有限公司 | 一种非螯合性非还原性铁死亡抑制剂及其制备方法和用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11673894B2 (en) | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | |
US11161850B2 (en) | Fused pyrazine derivatives as A2A / A2B inhibitors | |
US11168089B2 (en) | Fused pyrimidine derivatives as A2A / A2B inhibitors | |
US11220510B2 (en) | Pyrrole tricyclic compounds as A2A / A2B inhibitors | |
US11390624B2 (en) | Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors | |
KR20210116488A (ko) | 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물 | |
JP7490631B2 (ja) | A2a/a2b阻害剤としての縮合ピラジン誘導体 | |
EA046328B1 (ru) | Производные конденсированных пиразинов как ингибиторы a2a/a2b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, XIAOZHAO;GAN, PEI;HAN, HEEOON;AND OTHERS;SIGNING DATES FROM 20190729 TO 20190730;REEL/FRAME:049932/0265 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: INCYTE CORPORATION, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHAO, LE;HE, CHUNHONG;SIGNING DATES FROM 20200615 TO 20200617;REEL/FRAME:053058/0946 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |